Class	O
##ifying	X
the	O
evolutionary	O
and	O
ecological	O
features	O
of	O
neo	O
##p	X
##las	X
##ms	X
Neo	O
##p	X
##las	X
##ms	X
change	O
over	O
time	O
through	O
a	O
process	O
of	O
cell	O
-	X
level	X
evolution	O
,	O
driven	O
by	O
genetic	O
and	O
e	O
##pi	X
##gene	X
##tic	X
alterations	O
.	O

However	O
,	O
the	O
ecology	O
of	O
the	O
micro	O
##en	X
##vir	X
##on	X
##ment	X
of	O
a	O
neo	O
##p	X
##lastic	X
cell	O
determines	O
which	O
changes	O
provide	O
adaptive	O
benefits	O
.	O

There	O
is	O
widespread	O
recognition	O
of	O
the	O
importance	O
of	O
these	O
evolutionary	O
and	O
ecological	O
processes	O
in	O
cancer	O
,	O
but	O
to	O
date	O
,	O
no	O
system	O
has	O
been	O
proposed	O
for	O
drawing	O
clinical	O
##ly	X
relevant	O
distinction	O
##s	X
between	O
how	O
different	O
t	O
##umour	X
##s	X
are	O
evolving	O
.	O

On	O
the	O
basis	O
of	O
a	O
consensus	O
conference	O
of	O
experts	O
in	O
the	O
fields	O
of	O
cancer	O
evolution	O
and	O
cancer	O
ecology	O
,	O
we	O
propose	O
a	O
framework	O
for	O
class	O
##ifying	X
t	O
##umour	X
##s	X
that	O
is	O
based	O
on	O
four	O
relevant	O
components	O
.	O

These	O
are	O
the	O
diversity	O
of	O
neo	O
##p	X
##lastic	X
cells	O
(	O
in	O
##tra	X
##tum	X
##our	X
##al	X
he	O
##tero	X
##gene	X
##ity	X
)	O
and	O
changes	O
over	O
time	O
in	O
that	O
diversity	O
,	O
which	O
make	O
up	O
an	O
evolutionary	O
index	O
(	O
E	O
##vo	X
-	X
index	X
)	O
,	O
as	O
well	O
as	O
the	O
hazards	O
to	O
neo	O
##p	X
##lastic	X
cell	O
survival	O
and	O
the	O
resources	O
available	O
to	O
neo	O
##p	X
##lastic	X
cells	O
,	O
which	O
make	O
up	O
an	O
ecological	O
index	O
(	O
E	O
##co	X
-	X
index	X
)	O
.	O

We	O
review	O
evidence	O
demonstrating	O
the	O
importance	O
of	O
each	O
of	O
these	O
factors	O
and	O
describe	O
multiple	O
methods	O
that	O
can	O
be	O
used	O
to	O
measure	O
them	O
.	O

Development	O
of	O
this	O
classification	O
system	O
holds	O
promise	O
for	O
enabling	O
clinic	O
##ians	X
to	O
personal	O
##ize	X
optimal	O
interventions	O
based	O
on	O
the	O
e	O
##vo	X
##l	X
##va	X
##bility	X
of	O
the	O
patient	B-species
’	O
s	X
t	O
##umour	X
.	O

The	O
E	O
##vo	X
-	X
and	O
E	O
##co	X
-	X
in	X
##dices	X
provide	O
a	O
common	O
le	O
##xi	X
##con	X
for	O
communicating	O
about	O
how	O
neo	O
##p	X
##las	X
##ms	X
change	O
in	O
response	O
to	O
interventions	O
,	O
with	O
potential	O
implications	O
for	O
clinical	O
trials	O
,	O
personal	O
##ized	X
medicine	O
and	O
basic	O
cancer	O
research	O
.	O

Method	O
##s	X
We	O
convened	O
a	O
consensus	O
conference	O
of	O
experts	O
in	O
the	O
fields	O
of	O
cancer	O
evolution	O
and	O
cancer	O
ecology	O
to	O
lay	O
the	O
ground	O
##work	X
for	O
the	O
development	O
of	O
an	O
evolutionary	O
and	O
ecological	O
classification	O
system	O
.	O

The	O
initial	O
participants	B-species
(	O
Male	O
##y	X
,	O
A	O
##kt	X
##ip	X
##is	X
,	O
Graham	O
,	O
So	O
##tto	X
##ri	X
##va	X
,	O
Bo	O
##ddy	X
,	O
Jan	O
##is	X
##ze	X
##ws	X
##ka	X
,	O
Silva	O
,	O
G	O
##er	X
##linger	X
,	O
Anderson	O
,	O
Brown	O
and	O
Shi	O
##bat	X
##a	X
)	O
were	O
among	O
the	O
faculty	O
for	O
the	O
Evolution	O
and	O
E	O
##cology	X
of	O
Cancer	O
summer	O
school	O
funded	O
by	O
Well	O
##come	X
and	O
held	O
at	O
the	O
Well	O
##come	X
Gen	O
##ome	X
Campus	O
in	O
Hi	O
##nx	X
##ton	X
,	O
UK	O
,	O
in	O
July	O
of	O
2016	O
.	O

In	O
##put	X
from	O
all	O
participants	B-species
was	O
so	O
##licit	X
##ed	X
,	O
and	O
after	O
discussion	O
,	O
we	O
identified	O
areas	O
of	O
consensus	O
.	O

Afterwards	O
,	O
other	O
leaders	O
in	O
the	O
field	O
were	O
invited	O
to	O
join	O
the	O
effort	O
by	O
co	O
-	X
editing	X
and	O
discussing	O
the	O
developing	O
statement	O
.	O

All	O
authors	O
reviewed	O
and	O
approved	O
the	O
final	O
statement	O
.	O

Well	O
##come	X
Gen	O
##ome	X
Campus	O
Advanced	O
Course	O
##s	X
and	O
Scientific	O
Conference	O
##s	X
provided	O
financial	O
support	O
for	O
the	O
consensus	O
meeting	O
.	O

We	O
have	O
named	O
the	O
classification	O
system	O
,	O
with	O
their	O
permission	O
,	O
in	O
appreciation	O
of	O
Well	O
##come	X
’	O
s	X
support	O
.	O

Please	O
note	O
that	O
the	O
statement	O
reflects	O
the	O
opinions	O
of	O
the	O
authors	O
and	O
not	O
necessarily	O
those	O
of	O
Well	O
##come	X
.	O

Goals	O
and	O
guiding	O
principles	O
Our	O
development	O
of	O
this	O
framework	O
has	O
been	O
guided	O
by	O
several	O
goals	O
and	O
principles	O
.	O

We	O
agreed	O
that	O
an	O
ideal	O
classification	O
system	O
should	O
have	O
the	O
following	O
properties	O
.	O

First	O
,	O
it	O
must	O
be	O
able	O
to	O
alter	O
a	O
clinical	O
decision	O
point	O
.	O

Second	O
,	O
it	O
should	O
be	O
simple	O
enough	O
to	O
be	O
easily	O
remembered	O
and	O
applied	O
.	O

Third	O
,	O
it	O
should	O
also	O
al	O
##ign	X
with	O
our	O
current	O
understanding	O
of	O
the	O
dynamics	O
of	O
neo	O
##p	X
##las	X
##ms	X
.	O

Fourth	O
,	O
the	O
classification	O
system	O
should	O
be	O
general	O
enough	O
to	O
be	O
applied	O
across	O
different	O
types	O
of	O
neo	O
##p	X
##las	X
##m	X
,	O
recognizing	O
that	O
the	O
types	O
of	O
measurement	O
may	O
need	O
to	O
be	O
individual	O
##ized	X
to	O
a	O
given	O
type	O
of	O
cancer	O
.	O

This	O
framework	O
is	O
based	O
on	O
fundamental	O
theoretical	O
principles	O
underlying	O
evolutionary	O
and	O
ecological	O
dynamics	O
.	O

It	O
is	O
not	O
based	O
on	O
any	O
particular	O
ass	O
##ay	X
or	O
parameter	O
but	O
rather	O
captures	O
the	O
fundamental	O
drivers	O
of	O
t	O
##umour	X
evolution	O
.	O

This	O
is	O
a	O
necessary	O
first	O
step	O
that	O
we	O
hope	O
will	O
lead	O
to	O
many	O
method	O
##ological	X
and	O
measurement	O
innovations	O
to	O
q	O
##uant	X
##ify	X
the	O
key	O
components	O
of	O
t	O
##umour	X
evolution	O
and	O
ecology	O
that	O
we	O
identify	O
here	O
.	O

Because	O
the	O
evolution	O
of	O
cancer	O
is	O
still	O
a	O
relatively	O
new	O
field	O
,	O
there	O
is	O
still	O
uncertainty	O
about	O
the	O
best	O
ways	O
to	O
measure	O
and	O
describe	O
the	O
evolution	O
and	O
ecology	O
of	O
a	O
t	O
##umour	X
.	O

There	O
are	O
also	O
practical	O
considerations	O
in	O
the	O
construction	O
of	O
a	O
classification	O
system	O
.	O

If	O
a	O
t	O
##umour	X
could	O
be	O
classified	O
based	O
on	O
a	O
single	O
bio	O
##psy	X
from	O
standard	O
ass	O
##ays	X
such	O
as	O
those	O
that	O
can	O
be	O
done	O
on	O
formal	O
##in	X
-	X
fixed	X
para	O
##ffin	X
-	X
embedded	X
(	O
FF	O
##P	X
##E	X
)	O
tissue	O
or	O
standard	O
radio	O
##logical	X
images	O
,	O
translation	O
to	O
the	O
clinic	O
would	O
be	O
relatively	O
easy	O
.	O

However	O
,	O
studies	O
have	O
not	O
yet	O
been	O
done	O
to	O
test	O
whether	O
measures	O
of	O
the	O
e	O
##vo	X
##l	X
##va	X
##bility	X
of	O
a	O
t	O
##umour	X
from	O
a	O
single	O
bio	O
##psy	X
sample	O
are	O
sufficient	O
or	O
whether	O
multiple	O
samples	O
substantially	O
improve	O
predictions	O
of	O
clinical	O
outcomes	O
##15	X
.	O

We	O
h	O
##y	X
##pot	X
##hes	X
##ize	X
that	O
we	O
will	O
need	O
to	O
extensively	O
sample	O
neo	O
##p	X
##las	X
##ms	X
over	O
both	O
space	O
and	O
time	O
in	O
order	O
to	O
accurately	O
q	O
##uant	X
##ify	X
their	O
e	O
##vo	X
##l	X
##va	X
##bility	X
,	O
but	O
this	O
remains	O
an	O
open	O
question	O
.	O

It	O
is	O
clear	O
,	O
however	O
,	O
that	O
evolutionary	O
analyses	O
are	O
limited	O
if	O
the	O
c	O
##lon	X
##al	X
structure	O
of	O
the	O
primary	O
t	O
##umour	X
is	O
unknown	O
##18	X
.	O

The	O
use	O
of	O
cell	O
-	X
free	X
DNA	O
(	O
c	O
##f	X
##D	X
##NA	X
)	O
from	O
liquid	O
bio	O
##psy	X
samples	O
should	O
facilitate	O
longitudinal	O
studies	O
##19	X
,	O
although	O
de	O
##con	X
##vo	X
##lut	X
##ing	X
the	O
clone	O
##s	X
within	O
such	O
a	O
mixed	O
sample	O
remains	O
a	O
challenge	O
##20	X
.	O

Framework	O
for	O
class	O
##ifying	X
t	O
##umour	X
evolution	O
There	O
are	O
many	O
well	O
-	X
established	X
ways	O
to	O
class	O
##ify	X
t	O
##umour	X
##s	X
,	O
largely	O
based	O
on	O
extent	O
of	O
spread	O
and	O
m	O
##or	X
##phological	X
appearances	O
(	O
for	O
example	O
,	O
stage	O
and	O
grade	O
)	O
.	O

An	O
evolutionary	O
classification	O
system	O
would	O
au	O
##gment	X
current	O
schemes	O
by	O
further	O
capturing	O
the	O
e	O
##vo	X
##l	X
##va	X
##bility	X
of	O
a	O
t	O
##umour	X
.	O

How	O
much	O
intrinsic	O
genetic	O
instability	O
does	O
it	O
have	O
?	O

How	O
likely	O
is	O
it	O
to	O
respond	O
quickly	O
to	O
a	O
new	O
selective	O
pressure	O
such	O
as	O
a	O
therapeutic	O
intervention	O
?	O

For	O
example	O
,	O
rapid	O
progression	O
after	O
ch	O
##em	X
##otherapy	X
is	O
probably	O
driven	O
by	O
pre	O
-	X
existing	X
resistant	O
variants	O
,	O
and	O
therefore	O
,	O
failure	O
is	O
more	O
likely	O
in	O
t	O
##umour	X
##s	X
with	O
more	O
sub	O
##c	X
##lon	X
##al	X
diversity	O
(	O
in	O
##tra	X
##tum	X
##our	X
##al	X
he	O
##tero	X
##gene	X
##ity	X
)	O
6	O
.	O

Moreover	O
,	O
it	O
would	O
be	O
useful	O
to	O
class	O
##ify	X
evolution	O
through	O
time	O
.	O

For	O
example	O
,	O
a	O
second	O
bio	O
##psy	X
from	O
the	O
same	O
patient	B-species
after	O
therapy	O
may	O
reveal	O
minimal	O
diversity	O
,	O
indicating	O
a	O
re	O
##current	X
t	O
##umour	X
derived	O
from	O
a	O
single	O
clone	O
,	O
or	O
substantial	O
diversity	O
,	O
suggesting	O
intrinsic	O
resistance	O
by	O
the	O
majority	O
of	O
t	O
##umour	X
cells	O
.	O

There	O
was	O
widespread	O
agreement	O
at	O
the	O
consensus	O
conference	O
that	O
both	O
the	O
evolutionary	O
dynamics	O
of	O
the	O
neo	O
##p	X
##lastic	X
cells	O
themselves	O
(	O
cancer	O
cell	O
intrinsic	O
factors	O
)	O
and	O
the	O
micro	O
##en	X
##vir	X
##on	X
##ment	X
that	O
defines	O
the	O
ecology	O
of	O
those	O
cells	O
(	O
cancer	O
cell	O
ex	O
##tri	X
##ns	X
##ic	X
factors	O
)	O
are	O
important	O
in	O
predict	O
##ing	X
the	O
future	O
behaviour	O
and	O
response	O
of	O
a	O
t	O
##umour	X
.	O

To	O
capture	O
this	O
,	O
we	O
have	O
developed	O
a	O
framework	O
for	O
both	O
an	O
evolutionary	O
index	O
(	O
E	O
##vo	X
-	X
index	X
)	O
that	O
describes	O
the	O
intrinsic	O
e	O
##vo	X
##l	X
##va	X
##bility	X
of	O
the	O
neo	O
##p	X
##lastic	X
cell	O
population	O
and	O
an	O
ecological	O
index	O
(	O
E	O
##co	X
-	X
index	X
)	O
that	O
describes	O
potential	O
selective	O
pressures	O
imposed	O
by	O
the	O
surrounding	O
micro	O
##en	X
##vir	X
##on	X
##ment	X
.	O

The	O
E	O
##vo	X
-	X
index	X
The	O
E	O
##vo	X
-	X
index	X
(	O
D	O
#	O
Δ	O
#	O
)	O
is	O
a	O
combination	O
of	O
two	O
fundamental	O
components	O
:	O
the	O
diversity	O
(	O
D	O
)	O
or	O
in	O
##tra	X
##tum	X
##our	X
##al	X
he	O
##tero	X
##gene	X
##ity	X
of	O
the	O
neo	O
##p	X
##las	X
##m	X
and	O
how	O
it	O
changes	O
over	O
time	O
(	O
Δ	O
)	O
.	O

In	O
other	O
words	O
,	O
the	O
E	O
##vo	X
-	X
index	X
q	O
##uant	X
##ifies	X
he	O
##tero	X
##gene	X
##ity	X
in	O
both	O
space	O
and	O
time	O
(	O
F	O
##IG	X
.	O

1	O
##a	X
)	O
.	O

Both	O
diversity	O
and	O
changes	O
in	O
the	O
c	O
##lon	X
##al	X
structure	O
of	O
a	O
t	O
##umour	X
over	O
time	O
are	O
objective	O
measures	O
and	O
may	O
be	O
assessed	O
as	O
part	O
of	O
pre	O
##c	X
##lini	X
##cal	X
studies	O
or	O
clinical	O
trials	O
.	O

Di	O
##versity	X
The	O
he	O
##tero	X
##gene	X
##ity	X
that	O
is	O
currently	O
present	O
in	O
a	O
population	O
defines	O
its	O
capacity	O
to	O
respond	O
,	O
at	O
a	O
population	O
level	O
,	O
to	O
selective	O
pressures	O
.	O

This	O
diversity	O
is	O
the	O
fuel	O
for	O
the	O
engine	O
of	O
natural	O
selection	O
.	O

There	O
are	O
different	O
forms	O
of	O
diversity	O
,	O
including	O
genetic	O
diversity	O
,	O
e	O
##pi	X
##gene	X
##tic	X
diversity	O
,	O
p	O
##hen	X
##otypic	X
diversity	O
and	O
functional	O
diversity	O
.	O

Gene	O
##tic	X
diversity	O
can	O
predict	O
progression	O
to	O
invasive	O
cancer	O
##s	X
##12	X
,	X
13	X
as	O
well	O
as	O
re	O
##cu	X
##rrence	X
and	O
survival	O
##5	X
–	X
9	X
,	X
16	X
.	O

The	O
relationship	O
between	O
diversity	O
and	O
clinical	O
outcomes	O
is	O
not	O
universally	O
consistent	O
across	O
different	O
cancer	O
types	O
##6	X
,	O
16	O
and	O
can	O
be	O
complicated	O
(	O
B	O
##OX	X
1	O
)	O
.	O

Important	O
issues	O
in	O
the	O
measurement	O
of	O
diversity	O
in	O
neo	O
##p	X
##las	X
##ms	X
There	O
are	O
a	O
number	O
of	O
important	O
issues	O
and	O
open	O
questions	O
in	O
the	O
measurement	O
of	O
diversity	O
in	O
neo	O
##p	X
##las	X
##ms	X
:	O
How	O
are	O
clone	O
##s	X
defined	O
?	O

What	O
is	O
the	O
best	O
measure	O
of	O
diversity	O
?	O

How	O
do	O
the	O
measures	O
scale	O
up	O
to	O
g	O
##eno	X
##mic	X
ass	O
##ays	X
?	O

Are	O
there	O
non	O
##linear	X
associations	O
between	O
diversity	O
and	O
clinical	O
outcomes	O
?	O

Is	O
genetic	O
or	O
functional	O
diversity	O
more	O
predict	O
##ive	X
?	O

Is	O
it	O
sufficient	O
to	O
measure	O
diversity	O
in	O
the	O
primary	O
t	O
##umour	X
,	O
or	O
do	O
we	O
need	O
to	O
measure	O
diversity	O
in	O
the	O
meta	O
##sta	X
##ses	X
?	O

Is	O
it	O
adequate	O
to	O
estimate	O
diversity	O
from	O
bulk	O
bio	O
##psy	X
ass	O
##ays	X
,	O
or	O
do	O
we	O
need	O
to	O
measure	O
diversity	O
at	O
the	O
single	O
-	X
cell	X
level	O
?	O

In	O
order	O
to	O
measure	O
diversity	O
,	O
one	O
must	O
first	O
define	O
the	O
unit	O
that	O
is	O
being	O
measured	O
.	O

We	O
typically	O
cluster	O
cells	O
into	O
clone	O
##s	X
,	O
but	O
there	O
is	O
currently	O
no	O
general	O
definition	O
of	O
a	O
clone	O
.	O

Typically	O
,	O
for	O
ex	O
##ped	X
##ien	X
##cy	X
,	O
clone	O
##s	X
are	O
defined	O
as	O
the	O
set	O
of	O
cells	O
that	O
share	O
an	O
alter	O
##ation	X
of	O
interest	O
,	O
due	O
to	O
descent	O
from	O
a	O
common	O
ancestor	O
cell	O
.	O

A	O
more	O
string	O
##ent	X
definition	O
of	O
a	O
clone	O
is	O
a	O
set	O
of	O
cells	O
that	O
have	O
the	O
same	O
g	O
##eno	X
##type	X
based	O
on	O
some	O
ass	O
##ay	X
##12	X
,	O
13	O
.	O

However	O
,	O
that	O
definition	O
does	O
not	O
scale	O
well	O
to	O
whole	O
-	X
genome	X
ass	O
##ays	X
because	O
every	O
neo	O
##p	X
##lastic	X
cell	O
probably	O
displays	O
a	O
unique	O
genome	O
.	O

By	O
contrast	O
,	O
measures	O
of	O
diver	O
##gence	X
between	O
samples	O
only	O
become	O
more	O
accurate	O
as	O
ass	O
##ays	X
scale	O
up	O
to	O
the	O
g	O
##eno	X
##mic	X
level	O
##12	X
–	X
14	X
,	X
46	X
.	O

Another	O
alternative	O
would	O
be	O
to	O
re	O
##con	X
##st	X
##ru	X
##ct	X
the	O
cell	O
lineage	O
(	O
p	O
##hyl	X
##ogen	X
##y	X
)	O
of	O
a	O
neo	O
##p	X
##las	X
##m	X
and	O
then	O
define	O
clone	O
##s	X
based	O
on	O
the	O
topology	O
of	O
the	O
cell	O
lineage	O
,	O
although	O
this	O
is	O
not	O
straightforward	O
.	O

A	O
similar	O
problem	O
has	O
been	O
addressed	O
by	O
viral	O
and	O
bacterial	O
phylogenetic	O
##s	X
,	O
and	O
methods	O
may	O
be	O
borrowed	O
from	O
these	O
fields	O
##16	X
##7	X
,	O
168	O
.	O

It	O
is	O
not	O
clear	O
which	O
alterations	O
should	O
be	O
used	O
to	O
measure	O
diversity	O
.	O

Some	O
forms	O
of	O
diversity	O
,	O
such	O
as	O
mutations	O
in	O
ex	O
##ons	X
and	O
copy	O
number	O
changes	O
,	O
may	O
be	O
more	O
clinical	O
##ly	X
relevant	O
than	O
other	O
forms	O
of	O
diversity	O
.	O

However	O
,	O
Me	O
##rl	X
##o	X
and	O
colleagues	O
found	O
that	O
defining	O
a	O
clone	O
based	O
on	O
selective	O
##ly	X
advantage	O
##ous	X
mutations	O
and	O
defining	O
a	O
clone	O
based	O
on	O
evolution	O
##arily	X
neutral	O
mutations	O
both	O
predicted	O
progression	O
to	O
cancer	O
##13	X
.	O

Instead	O
of	O
genetics	O
,	O
one	O
could	O
measure	O
diversity	O
based	O
on	O
RNA	O
expression	O
or	O
other	O
p	O
##hen	X
##otypic	X
characteristics	O
##16	X
##9	X
,	X
170	X
.	O

Because	O
selection	O
acts	O
on	O
p	O
##hen	X
##otype	X
##s	X
,	O
this	O
may	O
be	O
a	O
better	O
predict	O
##or	X
of	O
a	O
the	O
e	O
##vo	X
##l	X
##va	X
##bility	X
of	O
a	O
t	O
##umour	X
than	O
genetic	O
measures	O
of	O
diversity	O
.	O

Gate	O
##n	X
##by	X
and	O
colleagues	O
have	O
argued	O
that	O
because	O
of	O
this	O
and	O
the	O
fact	O
that	O
there	O
are	O
many	O
different	O
g	O
##eno	X
##type	X
##s	X
that	O
can	O
produce	O
the	O
same	O
p	O
##hen	X
##otype	X
,	O
analysis	O
at	O
the	O
p	O
##hen	X
##otype	X
level	O
may	O
be	O
easier	O
and	O
provide	O
a	O
better	O
measure	O
of	O
e	O
##vo	X
##l	X
##va	X
##bility	X
than	O
analysis	O
at	O
the	O
g	O
##eno	X
##type	X
level	O
##17	X
##1	X
,	X
172	X
.	O

However	O
,	O
this	O
hypothesis	O
is	O
controversial	O
,	O
and	O
only	O
a	O
few	O
studies	O
have	O
tested	O
it	O
##17	X
##3	X
,	X
174	X
.	O

Unfortunately	O
,	O
the	O
literature	O
on	O
how	O
to	O
measure	O
functional	O
diversity	O
remains	O
poorly	O
developed	O
##30	X
.	O

The	O
diversity	O
of	O
the	O
primary	O
t	O
##umour	X
may	O
differ	O
from	O
that	O
of	O
any	O
meta	O
##sta	X
##ses	X
.	O

Because	O
the	O
primary	O
t	O
##umour	X
is	O
often	O
removed	O
and	O
it	O
is	O
the	O
meta	O
##sta	X
##ses	X
that	O
kill	O
patients	B-species
,	O
we	O
may	O
have	O
to	O
measure	O
diversity	O
within	O
and	O
between	O
any	O
meta	O
##sta	X
##ses	X
that	O
can	O
be	O
sampled	O
in	O
order	O
to	O
best	O
predict	O
clinical	O
outcomes	O
##2	X
.	O

It	O
is	O
currently	O
difficult	O
to	O
measure	O
many	O
lo	O
##ci	X
or	O
p	O
##hen	X
##otype	X
##s	X
at	O
the	O
single	O
-	X
cell	X
level	O
.	O

B	O
##ul	X
##k	X
se	O
##quencing	X
or	O
other	O
ass	O
##ays	X
at	O
the	O
bio	O
##psy	X
level	O
introduce	O
significant	O
bias	O
##es	X
.	O

For	O
example	O
,	O
recent	O
mutations	O
that	O
are	O
present	O
in	O
only	O
a	O
single	O
cell	O
or	O
a	O
small	O
minority	O
of	O
cells	O
are	O
missed	O
in	O
bulk	O
ass	O
##ays	X
,	O
bias	O
##ing	X
results	O
to	O
the	O
early	O
mutations	O
and	O
those	O
mutations	O
driving	O
c	O
##lon	X
##al	X
expansion	O
##17	X
##5	X
.	O

Preliminary	O
analyses	O
show	O
that	O
a	O
mixture	O
of	O
clone	O
##s	X
within	O
a	O
bio	O
##psy	X
sample	O
can	O
also	O
mi	O
##sle	X
##ad	X
any	O
analyses	O
based	O
on	O
estimates	O
of	O
shared	O
ancestry	O
,	O
such	O
as	O
phylogenetic	O
reconstruction	O
##17	X
##6	X
.	O

However	O
,	O
it	O
is	O
currently	O
difficult	O
to	O
ass	O
##ay	X
enough	O
lo	O
##ci	X
in	O
enough	O
single	O
cells	O
to	O
re	O
##con	X
##st	X
##ru	X
##ct	X
reliable	O
cell	O
lineage	O
##s	X
and	O
identify	O
rare	O
clone	O
##s	X
##17	X
##7	X
.	O

Di	O
##versity	X
can	O
be	O
a	O
pro	O
##xy	X
for	O
the	O
likelihood	O
that	O
a	O
resistant	O
clone	O
is	O
present	O
in	O
a	O
neo	O
##p	X
##las	X
##m	X
.	O

We	O
currently	O
do	O
not	O
know	O
all	O
the	O
mutations	O
and	O
e	O
##pi	X
##gene	X
##tic	X
alterations	O
that	O
make	O
a	O
neo	O
##p	X
##lastic	X
cell	O
resistant	O
to	O
a	O
particular	O
therapy	O
,	O
and	O
even	O
those	O
we	O
do	O
know	O
are	O
difficult	O
to	O
detect	O
if	O
they	O
are	O
present	O
in	O
only	O
a	O
small	O
region	O
of	O
the	O
t	O
##umour	X
.	O

Compared	O
with	O
ho	O
##mogeneous	X
neo	O
##p	X
##las	X
##ms	X
,	O
diverse	O
neo	O
##p	X
##las	X
##ms	X
are	O
more	O
likely	O
to	O
harbour	O
resistant	O
clone	O
##s	X
and	O
are	O
also	O
probably	O
more	O
likely	O
to	O
evolve	O
resistance	O
in	O
the	O
future	O
.	O

Multiple	O
forms	O
of	O
diversity	O
within	O
a	O
neo	O
##p	X
##las	X
##m	X
may	O
be	O
clinical	O
##ly	X
important	O
,	O
not	O
only	O
as	O
fuel	O
for	O
natural	O
selection	O
but	O
also	O
as	O
bio	O
##mark	X
##ers	X
of	O
clinical	O
##ly	X
target	O
##able	X
dynamics	O
.	O

For	O
example	O
,	O
if	O
high	O
levels	O
of	O
genetic	O
diversity	O
are	O
in	O
##dicative	X
of	O
high	O
levels	O
of	O
moderately	O
del	O
##eter	X
##ious	X
passenger	O
mutations	O
##21	X
,	O
22	O
,	O
then	O
suppress	O
##ing	X
mechanisms	O
in	O
the	O
cell	O
that	O
buffer	O
against	O
those	O
del	O
##eter	X
##ious	X
effects	O
,	O
such	O
as	O
ch	O
##aper	X
##one	X
proteins	O
,	O
should	O
prefer	O
##ential	X
##ly	X
harm	O
neo	O
##p	X
##lastic	X
cells	O
##21	X
.	O

Alternatively	O
,	O
diversity	O
may	O
be	O
in	O
##dicative	X
of	O
cooperation	O
between	O
clone	O
##s	X
,	O
through	O
mechanisms	O
such	O
as	O
cross	O
feeding	O
##23	X
–	X
27	X
.	O

These	O
mechanisms	O
of	O
cooperation	O
are	O
themselves	O
potential	O
therapeutic	O
targets	O
.	O

Theory	O
suggests	O
that	O
targeting	O
cancer	O
cell	O
cooperation	O
should	O
provide	O
weaker	O
selection	O
for	O
resistance	O
than	O
c	O
##yt	X
##oto	X
##xi	X
##c	X
the	O
##rap	X
##ies	X
##28	X
.	O

It	O
is	O
likely	O
that	O
not	O
all	O
forms	O
of	O
diversity	O
are	O
equal	O
,	O
and	O
future	O
work	O
must	O
test	O
which	O
are	O
clinical	O
##ly	X
relevant	O
.	O

It	O
may	O
be	O
the	O
case	O
that	O
measures	O
of	O
functional	O
diversity	O
or	O
even	O
p	O
##hen	X
##otypic	X
diversity	O
are	O
better	O
predict	O
##ors	X
of	O
clinical	O
outcomes	O
than	O
measures	O
of	O
genetic	O
diversity	O
(	O
as	O
many	O
genetic	O
mutations	O
will	O
have	O
no	O
p	O
##hen	X
##otypic	X
consequence	O
)	O
,	O
and	O
the	O
ideal	O
measures	O
may	O
vary	O
between	O
t	O
##umour	X
types	O
.	O

Me	O
##as	X
##uring	X
diversity	O
Of	O
the	O
four	O
components	O
of	O
the	O
classification	O
framework	O
,	O
the	O
largest	O
number	O
of	O
methods	O
has	O
been	O
developed	O
for	O
measuring	O
diversity	O
(	O
in	O
##tra	X
##tum	X
##our	X
##al	X
he	O
##tero	X
##gene	X
##ity	X
)	O
13	O
,	O
25	O
,	O
29	O
(	O
T	O
##AB	X
##LE	X
1	O
)	O
.	O

There	O
is	O
a	O
large	O
literature	O
in	O
ecology	O
on	O
the	O
q	O
##uant	X
##ification	X
of	O
diversity	O
##30	X
.	O

The	O
overall	O
diversity	O
of	O
a	O
large	O
area	O
,	O
or	O
landscape	O
(	O
gamma	O
diversity	O
)	O
,	O
can	O
be	O
broken	O
down	O
into	O
the	O
diversity	O
within	O
local	O
regions	O
(	O
alpha	O
diversity	O
)	O
and	O
the	O
differences	O
between	O
regions	O
(	O
beta	O
diversity	O
)	O
31	O
.	O

In	O
##here	X
##nt	X
in	O
this	O
definition	O
is	O
the	O
concept	O
that	O
measuring	O
diversity	O
requires	O
defining	O
the	O
spatial	O
scale	O
that	O
one	O
is	O
examining	O
.	O

One	O
might	O
define	O
within	O
-	X
region	X
diversity	O
as	O
the	O
diversity	O
measured	O
within	O
a	O
bio	O
##psy	X
sample	O
,	O
while	O
between	O
-	X
region	X
diversity	O
would	O
account	O
for	O
differences	O
between	O
bio	O
##psy	X
samples	O
in	O
multi	O
-	X
region	X
sampling	O
studies	O
.	O

Alternatively	O
,	O
one	O
could	O
take	O
a	O
sample	O
across	O
an	O
entire	O
t	O
##umour	X
,	O
perhaps	O
using	O
c	O
##f	X
##D	X
##NA	X
,	O
and	O
estimate	O
the	O
diversity	O
of	O
the	O
entire	O
population	O
.	O

Most	O
of	O
the	O
studies	O
to	O
date	O
have	O
focused	O
on	O
within	O
-	X
region	X
diversity	O
##5	X
,	O
6	O
,	O
32	O
,	O
33	O
or	O
the	O
diversity	O
of	O
the	O
entire	O
t	O
##umour	X
##12	X
–	X
14	X
,	O
25	O
.	O

The	O
use	O
of	O
ecological	O
statistics	O
for	O
measuring	O
between	O
-	X
region	X
diversity	O
in	O
t	O
##umour	X
##s	X
remains	O
relatively	O
une	O
##x	X
##p	X
##lore	X
##d	X
.	O

Established	O
measures	O
of	O
differences	O
between	O
micro	O
##bial	X
communities	O
##34	X
could	O
possibly	O
be	O
applied	O
to	O
measuring	O
differences	O
between	O
bio	O
##psy	X
samples	O
.	O

There	O
are	O
many	O
ways	O
to	O
measure	O
diversity	O
##30	X
and	O
a	O
number	O
of	O
challenges	O
to	O
measuring	O
diversity	O
in	O
neo	O
##p	X
##las	X
##ms	X
,	O
as	O
discussed	O
in	O
B	O
##OX	X
1	O
.	O

In	O
Barrett	B-disease
o	I-disease
##es	X
##op	X
##ha	X
##gus	X
,	O
Me	O
##rl	X
##o	X
and	O
colleagues	O
tested	O
many	O
of	O
those	O
measures	O
of	O
diversity	O
and	O
found	O
that	O
high	O
levels	O
of	O
diversity	O
were	O
predict	O
##ive	X
of	O
progression	O
to	O
cancer	O
,	O
regardless	O
of	O
the	O
measure	O
##13	X
,	O
14	O
.	O

Because	O
evolution	O
is	O
driven	O
by	O
the	O
fitness	O
out	O
##liers	X
##35	X
,	O
and	O
it	O
may	O
take	O
only	O
one	O
resistant	O
cell	O
at	O
diagnosis	O
to	O
eventually	O
cause	O
drug	O
resistance	O
or	O
re	O
##lap	X
##se	X
after	O
therapy	O
,	O
much	O
of	O
the	O
predict	O
##ive	X
value	O
of	O
measuring	O
diversity	O
may	O
lie	O
in	O
the	O
long	O
tail	O
of	O
rare	O
clone	O
##s	X
.	O

Because	O
of	O
this	O
,	O
we	O
recommend	O
using	O
either	O
a	O
count	O
of	O
the	O
number	O
of	O
clone	O
##s	X
(	O
‘	O
species	X
rich	O
##ness	X
’	O
)	O
or	O
Shannon	O
index	O
,	O
which	O
equally	O
weights	O
number	O
and	O
relative	O
abundance	O
of	O
clone	O
##s	X
,	O
to	O
q	O
##uant	X
##ify	X
diversity	O
##30	X
.	O

The	O
f	O
##eas	X
##ibility	X
of	O
obtaining	O
a	O
complete	O
picture	O
of	O
the	O
diversity	O
of	O
a	O
neo	O
##p	X
##las	X
##m	X
,	O
through	O
multi	O
-	X
region	X
sampling	O
or	O
c	O
##f	X
##D	X
##NA	X
,	O
varies	O
across	O
t	O
##umour	X
types	O
.	O

In	O
Barrett	B-disease
o	I-disease
##es	X
##op	X
##ha	X
##gus	X
,	O
bladder	B-disease
cancer	I-disease
and	O
pro	B-disease
##state	X
cancer	I-disease
,	O
multi	O
-	X
region	X
sampling	O
is	O
part	O
of	O
the	O
current	O
standard	O
of	O
care	O
##36	X
–	X
38	X
.	O

In	O
a	O
well	O
-	X
mixed	X
neo	O
##p	X
##las	X
##m	X
,	O
such	O
as	O
a	O
blood	O
cancer	O
,	O
a	O
single	O
sample	O
may	O
be	O
sufficient	O
,	O
but	O
it	O
requires	O
single	O
-	X
cell	X
ass	O
##ays	X
,	O
which	O
have	O
their	O
own	O
challenges	O
(	O
B	O
##OX	X
1	O
)	O
.	O

In	O
other	O
t	O
##umour	X
##s	X
that	O
are	O
difficult	O
to	O
sample	O
,	O
such	O
as	O
pan	B-disease
##cre	X
##atic	X
cancer	I-disease
##s	X
,	O
we	O
are	O
lucky	O
to	O
get	O
more	O
than	O
one	O
bio	O
##psy	X
sample	O
.	O

The	O
main	O
challenge	O
in	O
using	O
c	O
##f	X
##D	X
##NA	X
is	O
detect	O
##ing	X
it	O
in	O
serum	O
for	O
cancer	O
##s	X
that	O
have	O
not	O
yet	O
meta	O
##sta	X
##si	X
##zed	X
,	O
although	O
the	O
level	O
of	O
t	O
##umour	X
c	O
##f	X
##D	X
##NA	X
in	O
serum	O
varies	O
across	O
cancer	O
types	O
.	O

A	O
recent	O
study	O
was	O
able	O
to	O
detect	O
t	O
##umour	X
c	O
##f	X
##D	X
##NA	X
in	O
97	O
%	O
of	O
early	O
-	X
stage	X
lung	B-disease
sq	I-disease
##ua	X
##mous	X
cell	I-disease
car	I-disease
##cin	X
##oma	X
##s	X
but	O
only	O
19	O
%	O
of	O
early	O
-	X
stage	X
lung	B-disease
ad	O
##eno	X
##car	X
##cin	X
##oma	X
##s	X
##39	X
.	O

The	O
interpretation	O
of	O
the	O
diversity	O
of	O
a	O
neo	O
##p	X
##las	X
##m	X
depends	O
on	O
the	O
context	O
of	O
its	O
history	O
.	O

A	O
neo	O
##p	X
##las	X
##m	X
that	O
has	O
just	O
been	O
ho	O
##mo	X
##gen	X
##ized	X
by	O
a	O
therapy	O
that	O
killed	O
most	O
of	O
the	O
clone	O
##s	X
in	O
that	O
neo	O
##p	X
##las	X
##m	X
is	O
different	O
from	O
a	O
neo	O
##p	X
##las	X
##m	X
that	O
is	O
ho	O
##mogeneous	X
because	O
it	O
has	O
a	O
very	O
low	O
mutation	O
rate	O
and	O
has	O
not	O
had	O
enough	O
time	O
to	O
a	O
##cc	X
##um	X
##ulate	X
many	O
clone	O
##s	X
.	O

By	O
contrast	O
,	O
a	O
high	O
level	O
of	O
diversity	O
in	O
a	O
neo	O
##p	X
##las	X
##m	X
that	O
has	O
just	O
passed	O
through	O
a	O
therapeutic	O
bottle	O
##neck	X
may	O
be	O
a	O
sign	O
that	O
therapy	O
selected	O
for	O
a	O
m	O
##uta	X
##tor	X
p	O
##hen	X
##otype	X
##40	X
.	O

Because	O
of	O
this	O
com	O
##plication	X
,	O
we	O
agreed	O
that	O
we	O
must	O
measure	O
how	O
neo	O
##p	X
##las	X
##ms	X
are	O
changing	O
over	O
time	O
as	O
well	O
as	O
diversity	O
.	O

Change	O
over	O
time	O
There	O
are	O
a	O
variety	O
of	O
ways	O
that	O
a	O
neo	O
##p	X
##lastic	X
cell	O
population	O
changes	O
over	O
time	O
.	O

These	O
include	O
mutations	O
,	O
natural	O
selection	O
and	O
genetic	O
drift	O
.	O

One	O
important	O
parameter	O
of	O
change	O
over	O
time	O
is	O
the	O
mutation	O
rate	O
,	O
which	O
describes	O
how	O
fast	O
a	O
lineage	O
a	O
##cc	X
##um	X
##ulates	X
new	O
mutations	O
.	O

Of	O
course	O
,	O
there	O
are	O
different	O
mutation	O
rates	O
induced	O
by	O
each	O
mechanism	O
for	O
genetic	O
and	O
e	O
##pi	X
##gene	X
##tic	X
alter	O
##ation	X
,	O
including	O
mutation	O
signatures	O
induced	O
by	O
specific	O
agents	O
##41	X
as	O
well	O
as	O
te	O
##lo	X
##mere	X
erosion	O
,	O
non	O
-	X
ho	X
##mo	X
##log	X
##ous	X
re	O
##comb	X
##ination	X
,	O
other	O
forms	O
of	O
ch	O
##rom	X
##oso	X
##mal	X
instability	O
,	O
C	O
##p	X
##G	X
met	O
##hyl	X
##ation	X
and	O
his	O
-	X
tone	X
modifications	O
.	O

Which	O
mechanisms	O
are	O
relevant	O
will	O
depend	O
on	O
individual	O
t	O
##umour	X
##s	X
and	O
may	O
vary	O
across	O
the	O
different	O
clone	O
##s	X
within	O
the	O
same	O
t	O
##umour	X
.	O

When	O
we	O
talk	O
about	O
and	O
measure	O
mutation	O
rates	O
,	O
we	O
are	O
imp	O
##licit	X
##ly	X
assuming	O
that	O
mutations	O
happen	O
at	O
a	O
regular	O
rate	O
.	O

Evolution	O
##ary	X
biologist	O
##s	X
call	O
these	O
‘	O
molecular	X
clocks	O
’	O
(	O
R	O
##EF	X
.	O

42	O
)	O
.	O

However	O
,	O
a	O
catastrophic	O
mit	O
##osis	X
can	O
generate	O
ch	O
##rom	X
##oso	X
##mal	X
alterations	O
across	O
the	O
genome	O
in	O
a	O
single	O
event	O
##43	X
,	O
44	O
.	O

There	O
is	O
a	O
con	O
##tinuum	X
from	O
regular	O
,	O
gradual	O
,	O
clock	O
-	X
like	X
small	O
alterations	O
to	O
s	O
##poradic	X
,	O
pu	O
##nc	X
##tuated	X
,	O
large	O
alterations	O
.	O

For	O
example	O
,	O
a	O
lineage	O
may	O
evolve	O
different	O
mutation	O
rates	O
across	O
its	O
history	O
,	O
as	O
happens	O
with	O
the	O
evolution	O
of	O
a	O
m	O
##uta	X
##tor	X
p	O
##hen	X
##otype	X
##45	X
,	X
46	X
.	O

If	O
a	O
cell	O
lineage	O
can	O
change	O
suddenly	O
,	O
in	O
what	O
used	O
to	O
be	O
called	O
a	O
‘	O
mac	X
##rom	X
##uta	X
##tion	X
’	O
generating	O
a	O
‘	O
hopeful	X
monster	O
’	O
(	O
R	O
##EF	X
.	O

47	O
)	O
,	O
then	O
that	O
t	O
##umour	X
may	O
have	O
a	O
different	O
capacity	O
for	O
evolution	O
compared	O
with	O
a	O
t	O
##umour	X
that	O
is	O
con	O
##stra	X
##ined	X
to	O
evolve	O
through	O
the	O
slow	O
accumulation	O
of	O
mutations	O
with	O
small	O
p	O
##hen	X
##otypic	X
effects	O
.	O

There	O
is	O
a	O
large	O
cancer	O
literature	O
on	O
genetic	O
instability	O
that	O
is	O
relevant	O
here	O
##48	X
,	O
49	O
,	O
and	O
evidence	O
has	O
shown	O
that	O
t	O
##umour	X
##s	X
with	O
extremely	O
high	O
mutation	O
rates	O
may	O
have	O
a	O
better	O
pro	O
##gno	X
##sis	X
than	O
t	O
##umour	X
##s	X
with	O
moderate	O
rates	O
##6	X
,	O
11	O
,	O
21	O
,	O
22	O
,	O
50	O
.	O

High	O
levels	O
of	O
g	O
##eno	X
##mic	X
instability	O
may	O
make	O
it	O
difficult	O
for	O
cell	O
lineage	O
##s	X
to	O
maintain	O
the	O
adaptive	O
information	O
encoded	O
in	O
their	O
genome	O
##s	X
,	O
generating	O
non	O
-	X
viable	X
daughter	O
cells	O
,	O
and	O
may	O
also	O
produce	O
an	O
abundance	O
of	O
neo	O
-	X
anti	X
##gens	X
that	O
stimulate	O
an	O
anti	O
##tum	X
##our	X
immune	O
response	O
##6	X
.	O

Furthermore	O
,	O
high	O
mutation	O
rates	O
of	O
single	O
n	O
##uc	X
##leo	X
##tide	X
variants	O
can	O
generate	O
del	O
##eter	X
##ious	X
mutations	O
,	O
leading	O
to	O
the	O
fitness	O
decline	O
of	O
neo	O
##p	X
##lastic	X
cell	O
lineage	O
##s	X
in	O
a	O
form	O
of	O
Muller	O
’	O
s	X
rat	O
##chet	X
##21	X
,	O
51	O
.	O

This	O
may	O
even	O
cause	O
t	O
##umour	X
re	O
##gression	X
in	O
some	O
cases	O
##21	X
,	X
22	X
.	O

The	O
genetic	O
composition	O
of	O
a	O
population	O
changes	O
over	O
time	O
not	O
only	O
through	O
the	O
rate	O
at	O
which	O
mutations	O
arise	O
and	O
the	O
genetic	O
drift	O
of	O
those	O
all	O
##ele	X
##s	X
but	O
also	O
through	O
the	O
action	O
of	O
natural	O
selection	O
.	O

Natural	O
selection	O
leads	O
to	O
adaptations	O
,	O
such	O
as	O
drug	O
resistance	O
##5	X
##2	X
,	O
that	O
are	O
clinical	O
##ly	X
relevant	O
.	O

Det	O
##ec	X
##ting	X
and	O
measuring	O
natural	O
selection	O
is	O
likely	O
to	O
be	O
an	O
important	O
component	O
of	O
our	O
future	O
clinical	O
management	O
of	O
cancer	O
##s	X
.	O

The	O
classification	O
of	O
a	O
neo	O
##p	X
##las	X
##m	X
’	O
s	X
change	O
over	O
time	O
(	O
Δ	O
)	O
will	O
probably	O
need	O
to	O
take	O
into	O
account	O
both	O
the	O
speed	O
at	O
which	O
a	O
t	O
##umour	X
acquire	O
##s	X
genetic	O
or	O
e	O
##pi	X
##gene	X
##tic	X
alterations	O
,	O
or	O
changes	O
p	O
##hen	X
##otypic	X
##ally	X
,	O
including	O
how	O
fast	O
clone	O
##s	X
spread	O
by	O
natural	O
selection	O
,	O
as	O
well	O
as	O
the	O
tempo	O
of	O
that	O
change	O
(	O
from	O
gradual	O
to	O
pu	O
##nc	X
##tuated	X
)	O
.	O

The	O
appropriate	O
intervals	O
for	O
longitudinal	O
sampling	O
will	O
depend	O
on	O
the	O
rate	O
of	O
change	O
over	O
time	O
##53	X
.	O

Note	O
that	O
neutral	O
,	O
or	O
‘	O
passenger	X
’	O
,	O
mutations	O
should	O
not	O
be	O
ignored	O
in	O
these	O
calculations	O
because	O
selective	O
pressures	O
change	O
over	O
time	O
,	O
particularly	O
with	O
the	O
onset	O
of	O
therapy	O
.	O

Thus	O
,	O
resistance	O
mutations	O
,	O
which	O
may	O
be	O
del	O
##eter	X
##ious	X
or	O
neutral	O
in	O
the	O
absence	O
of	O
therapy	O
,	O
can	O
become	O
selective	O
##ly	X
advantage	O
##ous	X
for	O
neo	O
##p	X
##lastic	X
cells	O
exposed	O
to	O
therapy	O
##5	X
##4	X
.	O

Me	O
##as	X
##uring	X
change	O
over	O
time	O
Me	O
##as	X
##uring	X
change	O
over	O
time	O
is	O
complicated	O
,	O
whether	O
it	O
is	O
genetic	O
or	O
p	O
##hen	X
##otypic	X
change	O
(	O
T	O
##AB	X
##LE	X
1	O
)	O
.	O

F	O
##IG	X
##UR	X
##E	X
1	O
##b	X
illustrate	O
##s	X
a	O
simple	O
version	O
of	O
how	O
the	O
E	O
##vo	X
-	X
index	X
can	O
describe	O
evolutionary	O
changes	O
in	O
t	O
##umour	X
cell	O
populations	O
.	O

It	O
is	O
possible	O
for	O
there	O
to	O
be	O
change	O
over	O
time	O
but	O
for	O
diversity	O
to	O
remain	O
stable	O
,	O
with	O
a	O
dynamic	O
equilibrium	O
of	O
clone	O
##s	X
appearing	O
and	O
going	O
extinct	O
##14	X
.	O

For	O
single	O
samples	O
,	O
past	O
genetic	O
changes	O
over	O
time	O
can	O
be	O
indirectly	O
in	O
##ferred	X
based	O
on	O
mutation	O
frequencies	O
##17	X
,	X
55	X
.	O

So	O
##tto	X
##ri	X
##va	X
and	O
Graham	O
have	O
pioneered	O
methods	O
to	O
in	O
##fer	X
the	O
mutation	O
rate	O
and	O
to	O
distinguish	O
between	O
t	O
##umour	X
##s	X
that	O
are	O
dominated	O
by	O
genetic	O
drift	O
versus	O
those	O
with	O
evidence	O
of	O
natural	O
selection	O
after	O
transformation	O
.	O

In	O
the	O
absence	O
of	O
selection	O
,	O
mutations	O
that	O
occur	O
in	O
the	O
first	O
cell	O
division	O
after	O
transformation	O
should	O
appear	O
in	O
approximately	O
one	O
-	X
half	X
of	O
all	O
cancer	O
cells	O
,	O
mutations	O
that	O
occur	O
in	O
the	O
second	O
round	O
of	O
cell	O
division	O
should	O
appear	O
in	O
one	O
-	X
quarter	X
of	O
all	O
cancer	O
cells	O
,	O
and	O
so	O
on	O
##17	X
,	O
56	O
.	O

There	O
are	O
a	O
number	O
of	O
measures	O
of	O
genetic	O
change	O
over	O
time	O
from	O
population	O
genetics	O
that	O
might	O
be	O
used	O
on	O
neo	O
##p	X
##las	X
##ms	X
,	O
including	O
N	O
##ei	X
’	O
s	X
standard	O
genetic	O
distance	O
##5	X
##7	X
,	X
58	X
and	O
the	O
J	O
##ac	X
##card	X
similarity	O
coefficient	O
##5	X
##9	X
,	O
as	O
well	O
as	O
measures	O
of	O
beta	O
diversity	O
that	O
can	O
also	O
q	O
##uant	X
##ify	X
changes	O
in	O
a	O
community	O
over	O
time	O
,	O
such	O
as	O
Un	O
##i	X
##F	X
##rac	X
##34	X
or	O
the	O
fix	O
##ation	X
index	O
##60	X
.	O

The	O
degree	O
of	O
genetic	O
diver	O
##gence	X
between	O
samples	O
(	O
called	O
‘	O
n	X
##uc	X
##leo	X
##tide	X
diversity	O
’	O
in	O
molecular	O
population	O
genetics	O
)	O
provides	O
indirect	O
information	O
on	O
the	O
degree	O
of	O
change	O
over	O
time	O
.	O

Gene	O
##tic	X
diver	O
##gence	X
is	O
often	O
defined	O
as	O
the	O
percentage	O
of	O
the	O
genome	O
that	O
is	O
different	O
between	O
pairs	O
of	O
samples	O
##12	X
–	X
14	X
.	O

This	O
s	O
##tat	X
##istic	X
provides	O
predict	O
##ive	X
power	O
independent	O
of	O
the	O
number	O
of	O
clone	O
##s	X
for	O
predict	O
##ing	X
progression	O
##12	X
,	O
13	O
,	O
supporting	O
the	O
framework	O
of	O
including	O
both	O
diversity	O
and	O
change	O
over	O
time	O
in	O
the	O
E	O
##vo	X
-	X
index	X
.	O

Note	O
that	O
the	O
same	O
c	O
##lon	X
##al	X
structure	O
can	O
have	O
radical	O
##ly	X
different	O
degrees	O
of	O
genetic	O
diver	O
##gence	X
(	O
F	O
##IG	X
.	O

2	O
)	O
.	O

Male	O
##y	X
and	O
colleagues	O
have	O
calculated	O
a	O
mean	O
pair	O
##wise	X
diver	O
##gence	X
score	O
between	O
all	O
pairs	O
of	O
samples	O
from	O
a	O
neo	O
##p	X
##las	X
##m	X
##12	X
–	X
14	X
.	O

As	O
the	O
chance	O
that	O
two	O
samples	O
come	O
from	O
the	O
same	O
clone	O
(	O
and	O
so	O
have	O
minimal	O
diver	O
##gence	X
)	O
depends	O
on	O
the	O
size	O
of	O
the	O
clone	O
,	O
the	O
mean	O
pair	O
##wise	X
diver	O
##gence	X
blend	O
##s	X
the	O
degree	O
of	O
diver	O
##gence	X
with	O
clone	O
size	O
measures	O
(	O
and	O
so	O
blend	O
##s	X
D	O
with	O
Δ	O
)	O
.	O

One	O
of	O
the	O
primary	O
tools	O
for	O
measuring	O
change	O
over	O
time	O
in	O
evolutionary	O
biology	O
is	O
phylogenetic	O
in	O
##ference	X
,	O
which	O
re	O
##con	X
##st	X
##ru	X
##cts	X
the	O
history	O
of	O
a	O
neo	O
##p	X
##las	X
##m	X
##6	X
##1	X
,	X
62	X
.	O

Ph	O
##yl	X
##ogen	X
##etic	X
methods	O
can	O
be	O
used	O
to	O
describe	O
and	O
q	O
##uant	X
##ify	X
diversity	O
patterns	O
as	O
well	O
as	O
rates	O
of	O
evolution	O
across	O
both	O
space	O
and	O
time	O
.	O

Multiple	O
phylogenetic	O
approaches	O
have	O
been	O
developed	O
in	O
recent	O
years	O
to	O
study	O
t	O
##umour	X
evolution	O
within	O
a	O
patient	B-species
,	O
both	O
for	O
bulk	O
and	O
single	O
-	X
cell	X
data	O
and	O
from	O
a	O
variety	O
of	O
data	O
types	O
##20	X
,	O
63	O
.	O

These	O
methods	O
depend	O
on	O
evolutionary	O
models	O
for	O
the	O
likelihood	O
of	O
molecular	O
alterations	O
occurring	O
in	O
neo	O
##p	X
##lastic	X
cell	O
lineage	O
##s	X
,	O
although	O
the	O
development	O
of	O
these	O
models	O
is	O
still	O
in	O
its	O
infancy	O
.	O

All	O
of	O
the	O
measures	O
discussed	O
so	O
far	O
can	O
be	O
calculated	O
from	O
a	O
single	O
time	O
##point	X
.	O

Of	O
course	O
,	O
the	O
degree	O
and	O
nature	O
of	O
change	O
over	O
time	O
can	O
be	O
better	O
measured	O
directly	O
with	O
longitudinal	O
samples	O
.	O

Mini	O
##mal	X
##ly	X
invasive	O
ass	O
##ays	X
,	O
such	O
as	O
se	O
##quencing	X
c	O
##f	X
##D	X
##NA	X
from	O
longitudinal	O
blood	O
samples	O
,	O
could	O
reveal	O
the	O
action	O
of	O
natural	O
or	O
artificial	O
selection	O
in	O
patients	B-species
.	O

Inc	O
##or	X
##por	X
##ation	X
of	O
the	O
E	O
##vo	X
-	X
index	X
into	O
clinical	O
trials	O
can	O
better	O
describe	O
,	O
in	O
evolutionary	O
terms	O
,	O
why	O
interventions	O
fail	O
.	O

Most	O
human	B-species
t	O
##umour	X
##s	X
at	O
the	O
time	O
of	O
clinical	O
presentation	O
contain	O
multiple	O
large	O
clone	O
##s	X
##6	X
,	O
16	O
and	O
probably	O
many	O
more	O
small	O
clone	O
##s	X
##64	X
,	O
65	O
,	O
and	O
re	O
##lap	X
##se	X
without	O
a	O
reduction	O
in	O
diversity	O
would	O
probably	O
imply	O
intrinsic	O
resistance	O
or	O
perhaps	O
that	O
an	O
intervention	O
resulted	O
in	O
increased	O
m	O
##uta	X
##genesis	X
.	O

By	O
contrast	O
,	O
re	O
##lap	X
##se	X
with	O
less	O
diversity	O
(	O
D	O
##1	X
)	O
implies	O
a	O
bottle	O
##neck	X
effect	O
where	O
only	O
a	O
minority	O
of	O
t	O
##umour	X
cells	O
survived	O
the	O
intervention	O
,	O
probably	O
indicating	O
selection	O
for	O
one	O
or	O
a	O
few	O
resistant	O
clone	O
##s	X
.	O

The	O
E	O
##co	X
-	X
index	X
From	O
the	O
perspective	O
of	O
an	O
organism	O
or	O
a	O
neo	O
##p	X
##lastic	X
cell	O
,	O
its	O
ecology	O
can	O
be	O
broadly	O
described	O
by	O
two	O
characteristics	O
:	O
hazards	O
(	O
H	O
)	O
and	O
resources	O
(	O
R	O
)	O
66	O
–	X
69	X
(	O
F	O
##IG	X
.	O

3	O
)	O
.	O

Ha	O
##zard	X
##s	X
,	O
here	O
,	O
are	O
the	O
things	O
that	O
can	O
kill	O
a	O
cell	O
.	O

The	O
relevant	O
resources	O
required	O
for	O
cell	O
maintenance	O
and	O
growth	O
are	O
many	O
and	O
varied	O
;	O
whatever	O
may	O
potentially	O
limit	O
the	O
growth	O
of	O
the	O
neo	O
##p	X
##lastic	X
cell	O
population	O
##6	X
##6	X
.	O

Note	O
that	O
hazards	O
and	O
resources	O
here	O
are	O
understood	O
from	O
the	O
perspective	O
of	O
the	O
neo	O
##p	X
##lastic	X
cell	O
,	O
not	O
the	O
patient	B-species
.	O

This	O
is	O
an	O
important	O
point	O
from	O
ecology	O
—	O
we	O
can	O
understand	O
the	O
evolution	O
and	O
responses	O
of	O
a	O
population	O
best	O
when	O
we	O
take	O
the	O
perspective	O
of	O
an	O
organism	O
in	O
that	O
population	O
##70	X
.	O

From	O
an	O
ecological	O
perspective	O
,	O
the	O
hazard	O
and	O
resource	O
profiles	O
for	O
a	O
species	O
select	O
for	O
the	O
particular	O
life	O
history	O
strategies	O
of	O
that	O
species	O
.	O

A	O
##kt	X
##ip	X
##is	X
and	O
colleagues	O
argued	O
that	O
the	O
same	O
principles	O
are	O
true	O
for	O
neo	O
##p	X
##lastic	X
cells	O
##7	X
##1	X
.	O

Species	O
that	O
are	O
exposed	O
to	O
high	O
levels	O
of	O
hazard	O
tend	O
to	O
evolve	O
fast	O
life	O
history	O
strategies	O
,	O
re	O
##p	X
##rod	X
##uc	X
##ing	X
quickly	O
and	O
investing	O
little	O
in	O
maintenance	O
and	O
survival	O
.	O

Organ	O
##isms	X
subjected	O
to	O
hazards	O
generally	O
leave	O
behind	O
higher	O
levels	O
of	O
une	O
##x	X
##p	X
##lo	X
##ited	X
resources	O
.	O

E	O
##cos	X
##ys	X
##tem	X
##s	X
with	O
high	O
or	O
flu	O
##ct	X
##uating	X
resource	O
supplies	O
favour	O
organisms	O
that	O
can	O
rapidly	O
reproduce	O
to	O
exploit	O
those	O
opportunities	O
.	O

This	O
select	O
##s	X
for	O
speed	O
over	O
efficiency	O
and	O
can	O
result	O
in	O
very	O
high	O
population	O
den	O
##sities	X
but	O
also	O
flu	O
##ct	X
##uating	X
levels	O
of	O
une	O
##x	X
##p	X
##lo	X
##ited	X
resources	O
.	O

By	O
contrast	O
,	O
populations	O
that	O
have	O
few	O
hazards	O
and	O
a	O
steady	O
supply	O
of	O
resources	O
will	O
tend	O
to	O
expand	O
to	O
the	O
carrying	O
capacity	O
of	O
the	O
habitat	O
,	O
at	O
which	O
point	O
natural	O
selection	O
favour	O
##s	X
organisms	O
that	O
can	O
best	O
compete	O
for	O
and	O
efficiently	O
utilize	O
the	O
limiting	O
resources	O
##7	X
##2	X
.	O

The	O
he	O
##tero	X
##gene	X
##ity	X
of	O
resources	O
and	O
hazards	O
across	O
space	O
also	O
has	O
important	O
impacts	O
on	O
the	O
future	O
evolution	O
of	O
cancer	O
cell	O
populations	O
and	O
pro	O
##gno	X
##sis	X
for	O
patients	O
##7	X
##3	X
,	X
74	X
.	O

Ha	O
##zard	X
##s	X
There	O
are	O
multiple	O
sources	O
of	O
hazards	O
for	O
neo	O
##p	X
##lastic	X
cells	O
,	O
including	O
immune	O
cells	O
,	O
to	O
##xin	X
##s	X
,	O
waste	O
products	O
,	O
micro	O
##or	X
##gan	X
##isms	X
and	O
anti	O
##can	X
##cer	X
the	O
##rap	X
##ies	X
.	O

There	O
is	O
good	O
evidence	O
that	O
immune	O
pre	O
##dation	X
is	O
associated	O
with	O
improved	O
cancer	O
pro	O
##gno	X
##sis	X
##7	X
##3	X
,	O
75	O
–	X
83	X
.	O

Furthermore	O
,	O
there	O
is	O
emerging	O
evidence	O
linking	O
high	O
mutation	O
loads	O
that	O
result	O
in	O
the	O
formation	O
of	O
neo	O
-	X
anti	X
##gens	X
with	O
immune	O
pre	O
##dation	X
and	O
better	O
survival	O
in	O
patients	B-species
treated	O
with	O
immune	O
check	O
##point	X
blockade	O
the	O
##rap	X
##ies	X
##8	X
##4	X
–	X
86	X
.	O

In	O
addition	O
,	O
a	O
high	O
sub	O
##c	X
##lon	X
##al	X
neo	O
-	X
anti	X
##genic	X
burden	O
is	O
associated	O
with	O
worse	O
outcomes	O
in	O
lung	B-disease
cancer	I-disease
when	O
patients	B-species
are	O
treated	O
with	O
check	O
##point	X
inhibitor	O
##s	X
##8	X
##7	X
.	O

These	O
data	O
suggest	O
that	O
sub	O
##c	X
##lon	X
##al	X
neo	O
-	X
anti	X
##gens	X
might	O
imp	O
##ede	X
c	O
##yt	X
##oto	X
##xi	X
##c	X
immune	O
responses	O
against	O
neo	O
-	X
anti	X
##gens	X
that	O
are	O
present	O
in	O
every	O
t	O
##umour	X
cell	O
.	O

Other	O
hazards	O
faced	O
by	O
neo	O
##p	X
##lastic	X
cells	O
include	O
the	O
accumulation	O
of	O
waste	O
products	O
in	O
their	O
micro	O
-	X
environments	X
##6	X
##7	X
,	O
69	O
,	O
88	O
,	O
89	O
.	O

This	O
may	O
include	O
la	O
##ctic	X
acid	O
and	O
la	O
##ct	X
##ate	X
build	O
-	X
up	X
from	O
g	O
##ly	X
##co	X
##lysis	X
##8	X
##8	X
,	X
90	X
as	O
well	O
as	O
reactive	O
oxygen	O
species	O
from	O
excessive	O
cellular	O
proliferation	O
##9	X
##1	X
.	O

Met	O
##hyl	X
##gly	X
##ox	X
##al	X
##9	X
##2	X
,	X
93	X
,	O
ni	O
##tric	X
oxide	O
##9	X
##4	X
,	X
95	X
and	O
advanced	O
g	O
##ly	X
##cation	X
end	O
products	O
##9	X
##6	X
,	O
97	X
have	O
also	O
been	O
implicated	O
as	O
toxic	O
waste	O
products	O
in	O
cancer	O
micro	O
##en	X
##vir	X
##on	X
##ments	X
.	O

The	O
role	O
of	O
the	O
micro	O
##bio	X
##me	X
in	O
cancer	O
is	O
complicated	O
and	O
largely	O
unknown	O
.	O

While	O
some	O
micro	O
##or	X
##gan	X
##isms	X
may	O
promote	O
t	O
##umour	X
##s	X
##9	X
##8	X
,	O
99	O
,	O
others	O
have	O
anti	O
##tum	X
##our	X
effects	O
##9	X
##8	X
,	O
enhancing	O
the	O
efficacy	O
of	O
ch	O
##em	X
##otherapy	X
##100	X
.	O

Thus	O
,	O
micro	O
-	X
organisms	X
may	O
act	O
as	O
both	O
resources	O
and	O
hazards	O
for	O
neo	O
##p	X
##lastic	X
cells	O
.	O

Me	O
##as	X
##uring	X
hazards	O
The	O
current	O
best	O
measures	O
of	O
hazards	O
for	O
a	O
neo	O
##p	X
##lastic	X
cell	O
depend	O
on	O
measures	O
of	O
immune	O
pre	O
##dation	X
(	O
T	O
##AB	X
##LE	X
1	O
)	O
.	O

There	O
is	O
a	O
large	O
literature	O
on	O
the	O
association	O
between	O
in	O
##fi	X
##lt	X
##rating	X
l	O
##ymph	X
##ocytes	X
and	O
favourable	O
pro	O
##gno	X
##sis	X
in	O
cancer	O
##7	X
##3	X
,	O
75	O
–	X
83	X
.	O

In	O
addition	O
,	O
a	O
pan	O
-	X
cancer	X
analysis	O
revealed	O
T	O
cell	O
signatures	O
to	O
be	O
broadly	O
favourable	O
pro	O
##gno	X
##stic	X
markers	O
across	O
25	O
cancer	O
types	O
##10	X
##1	X
.	O

G	O
##alo	X
##n	X
and	O
colleagues	O
have	O
found	O
that	O
a	O
signature	O
of	O
activated	O
T	O
cells	O
from	O
bulk	O
t	O
##umour	X
samples	O
is	O
also	O
strongly	O
predict	O
##ive	X
of	O
favourable	O
survival	O
##7	X
##6	X
–	X
78	X
,	X
83	X
.	O

Yuan	O
and	O
colleagues	O
have	O
shown	O
that	O
ha	O
##ema	X
##to	X
##xy	X
##lin	X
and	O
e	O
##os	X
##in	X
images	O
can	O
be	O
computational	O
##ly	X
anal	O
##ys	X
##ed	X
to	O
identify	O
neo	O
##p	X
##lastic	X
cells	O
,	O
fi	O
##bro	X
##blast	X
##s	X
and	O
l	O
##ymph	X
##ocytes	X
and	O
,	O
further	O
##more	X
,	O
that	O
patients	B-species
with	O
breast	B-disease
cancer	I-disease
who	O
show	O
co	O
##loc	X
##ali	X
##zation	X
of	O
neo	O
##p	X
##lastic	X
cells	O
with	O
l	O
##ymph	X
##ocytes	X
in	O
the	O
t	O
##umour	X
have	O
a	O
better	O
pro	O
##gno	X
##sis	X
than	O
patients	B-species
with	O
t	O
##umour	X
##s	X
in	O
which	O
the	O
l	O
##ymph	X
##ocytes	X
are	O
separated	O
from	O
the	O
neo	O
##p	X
##lastic	X
cells	O
##75	X
.	O

This	O
is	O
based	O
on	O
a	O
standard	O
ecological	O
s	O
##tat	X
##istic	X
,	O
the	O
Mo	O
##ris	X
##ita	X
–	X
Horn	X
index	O
##10	X
##2	X
,	O
for	O
q	O
##uant	X
##ifying	X
statistical	O
##ly	X
significant	O
co	O
##loc	X
##ali	X
##zation	X
in	O
order	O
to	O
detect	O
ecological	O
interactions	O
(	O
in	O
this	O
case	O
,	O
pre	O
##dation	X
)	O
.	O

These	O
results	O
suggest	O
that	O
immune	O
pre	O
##dation	X
is	O
a	O
major	O
form	O
of	O
hazard	O
for	O
a	O
neo	O
##p	X
##lastic	X
cell	O
,	O
and	O
measures	O
of	O
that	O
pre	O
##dation	X
should	O
be	O
a	O
central	O
component	O
of	O
the	O
ecological	O
index	O
.	O

While	O
much	O
research	O
has	O
investigated	O
the	O
potentially	O
toxic	O
effects	O
of	O
low	O
pH	O
(	O
R	O
##EF	X
##S	X
103	O
,	O
104	O
)	O
,	O
fewer	O
studies	O
have	O
examined	O
the	O
fitness	O
consequences	O
to	O
cancer	O
cells	O
from	O
various	O
meta	O
##bol	X
##ites	X
.	O

Future	O
research	O
should	O
determine	O
the	O
effects	O
of	O
different	O
concentrations	O
of	O
put	O
##ative	X
toxic	O
meta	O
##bol	X
##ites	X
on	O
cancer	O
cell	O
survival	O
and	O
proliferation	O
in	O
both	O
cell	O
culture	O
experiments	O
and	O
mouse	B-species
models	O
.	O

Me	O
##as	X
##ure	X
##ments	X
of	O
anti	O
##can	X
##cer	X
drug	O
concentrations	O
in	O
the	O
t	O
##umour	X
are	O
also	O
likely	O
to	O
q	O
##uant	X
##ify	X
important	O
hazards	O
for	O
the	O
neo	O
##p	X
##lastic	X
cells	O
.	O

In	O
addition	O
,	O
the	O
micro	O
##bio	X
##me	X
(	O
including	O
the	O
v	O
##iro	X
##me	X
)	O
of	O
t	O
##umour	X
##s	X
can	O
be	O
surveyed	O
to	O
reveal	O
micro	O
##bial	X
hazards	O
for	O
the	O
neo	O
##p	X
##lastic	X
cells	O
##10	X
##5	X
.	O

Resources	O
Resources	O
,	O
including	O
oxygen	O
,	O
glucose	O
,	O
micro	O
##nut	X
##rient	X
##s	X
,	O
survival	O
signals	O
,	O
growth	O
signals	O
and	O
space	O
,	O
are	O
also	O
critical	O
to	O
the	O
future	O
behaviour	O
of	O
a	O
t	O
##umour	X
.	O

Sur	O
##p	X
##rising	X
##ly	X
little	O
is	O
known	O
about	O
the	O
interactions	O
between	O
cell	O
metabolism	O
and	O
the	O
availability	O
of	O
key	O
resources	O
,	O
which	O
e	O
##cologist	X
##s	X
term	O
the	O
organism	O
’	O
s	X
‘	O
for	X
##aging	X
ecology	O
’	O
.	O

Almost	O
all	O
cancer	O
##s	X
rely	O
on	O
g	O
##ly	X
##co	X
##ly	X
##tic	X
as	O
opposed	O
to	O
a	O
##ero	X
##bic	X
metabolism	O
,	O
suggesting	O
that	O
resources	O
can	O
select	O
for	O
t	O
##umour	X
p	O
##hen	X
##otype	X
##s	X
##10	X
##6	X
,	O
107	O
.	O

From	O
nature	O
,	O
we	O
know	O
that	O
selection	O
favour	O
##s	X
feeding	O
behaviour	O
##s	X
that	O
balance	O
speed	O
,	O
efficiency	O
and	O
safety	O
##10	X
##8	X
.	O

There	O
must	O
be	O
strong	O
selection	O
for	O
cancer	O
cells	O
to	O
do	O
the	O
same	O
(	O
for	O
example	O
,	O
through	O
up	O
##re	X
##gu	X
##lation	X
of	O
transport	O
##ers	X
such	O
as	O
glucose	O
transport	O
##er	X
type	O
1	O
,	O
er	O
##yt	X
##hr	X
##oc	X
##yte	X
/	X
brain	X
(	O
G	B-gene
##L	X
##UT	X
##1	X
,	O
also	O
known	O
as	O
SL	B-gene
##C	X
##2	X
##A	X
##1	X
)	O
109	O
)	O
.	O

Me	O
##as	X
##uring	X
which	O
resources	O
limit	O
the	O
population	O
size	O
and	O
proliferation	O
of	O
neo	O
##p	X
##lastic	X
cells	O
would	O
allow	O
researchers	O
to	O
identify	O
some	O
of	O
the	O
strongest	O
selective	O
pressures	O
on	O
the	O
t	O
##umour	X
and	O
to	O
predict	O
how	O
it	O
will	O
change	O
in	O
the	O
future	O
.	O

This	O
approach	O
would	O
also	O
provide	O
targets	O
for	O
further	O
reducing	O
the	O
e	O
##vo	X
##l	X
##va	X
##bility	X
of	O
the	O
neo	O
##p	X
##las	X
##m	X
by	O
lowering	O
the	O
carrying	O
capacity	O
of	O
its	O
micro	O
##en	X
##vir	X
##on	X
##ment	X
.	O

In	O
the	O
broader	O
ecological	O
literature	O
,	O
consumer	O
–	X
resource	X
theory	O
##11	X
##0	X
shows	O
that	O
resource	O
supply	O
,	O
de	O
##ple	X
##tion	X
and	O
availability	O
affect	O
population	O
growth	O
rates	O
,	O
population	O
sizes	O
and	O
competition	O
between	O
different	O
species	O
(	O
that	O
is	O
,	O
distinct	O
c	O
##lon	X
##al	X
lineage	O
##s	X
)	O
.	O

Resource	O
supply	O
represents	O
the	O
rate	O
at	O
which	O
new	O
resources	O
enter	O
the	O
system	O
(	O
in	O
this	O
case	O
,	O
the	O
t	O
##umour	X
)	O
and	O
the	O
rate	O
at	O
which	O
resources	O
become	O
available	O
through	O
nut	O
##rient	X
cycling	O
within	O
the	O
system	O
.	O

The	O
aggregate	O
consumption	O
of	O
all	O
cells	O
de	O
##ple	X
##tes	X
the	O
resources	O
,	O
typically	O
to	O
levels	O
much	O
lower	O
than	O
experienced	O
by	O
normal	O
tissues	O
##11	X
##1	X
.	O

In	O
fact	O
,	O
glucose	O
becomes	O
depleted	O
below	O
levels	O
detect	O
##able	X
by	O
most	O
analyses	O
##11	X
##2	X
.	O

However	O
,	O
in	O
some	O
cases	O
,	O
immune	O
pre	O
##dation	X
and	O
flu	O
##ct	X
##uations	X
in	O
resource	O
supply	O
can	O
prevent	O
the	O
complete	O
exploitation	O
of	O
resources	O
##11	X
##3	X
,	X
114	X
,	O
leaving	O
patches	O
of	O
residual	O
resources	O
available	O
for	O
future	O
exploitation	O
##11	X
##5	X
.	O

The	O
potential	O
resources	O
for	O
a	O
t	O
##umour	X
include	O
the	O
contents	O
of	O
plasma	O
and	O
the	O
meta	O
##bol	X
##ites	X
synthesized	O
and	O
secret	O
##ed	X
by	O
the	O
normal	O
cells	O
of	O
the	O
t	O
##umour	X
and	O
its	O
micro	O
##en	X
##vir	X
##on	X
##ment	X
.	O

Hence	O
,	O
the	O
list	O
includes	O
proteins	O
(	O
album	O
##ins	X
,	O
g	O
##lo	X
##bul	X
##ins	X
and	O
fi	O
##bri	X
##no	X
##gens	X
)	O
,	O
glucose	O
,	O
amino	O
acids	O
,	O
fatty	O
acids	O
,	O
hormones	O
,	O
electro	O
##ly	X
##tes	X
,	O
oxygen	O
and	O
trace	O
elements	O
.	O

The	O
functional	O
response	O
and	O
the	O
value	O
of	O
the	O
resources	O
to	O
the	O
consumer	O
are	O
dictated	O
by	O
nutrition	O
##al	X
relationships	O
##11	X
##6	X
.	O

In	O
some	O
cases	O
,	O
lack	O
of	O
a	O
resource	O
may	O
trigger	O
s	O
##tas	X
##is	X
,	O
but	O
in	O
others	O
,	O
it	O
may	O
lead	O
to	O
cell	O
death	O
or	O
di	O
##sper	X
##sal	X
##11	X
##7	X
.	O

At	O
the	O
moment	O
,	O
there	O
are	O
many	O
open	O
questions	O
about	O
the	O
in	O
##tra	X
##tum	X
##our	X
##al	X
cycle	O
of	O
critical	O
nutrients	O
other	O
than	O
carbon	O
and	O
nitrogen	O
(	O
that	O
is	O
,	O
phosphate	O
,	O
iron	O
,	O
copper	O
,	O
etc	O
.	O
)	O
118	O
.	O

These	O
nut	O
##rient	X
cycles	O
may	O
contain	O
valuable	O
therapeutic	O
targets	O
.	O

Some	O
resources	O
,	O
particularly	O
growth	O
and	O
survival	O
signals	O
,	O
may	O
be	O
provided	O
by	O
the	O
neighbouring	O
s	O
##trom	X
##al	X
cells	O
##11	X
##9	X
,	X
120	X
.	O

N	O
##ut	X
##rient	X
##s	X
may	O
also	O
be	O
provided	O
by	O
the	O
s	O
##trom	X
##a	X
.	O

P	O
##yr	X
##u	X
##vate	X
and	O
la	O
##ct	X
##ate	X
can	O
be	O
supplied	O
to	O
cancer	O
cells	O
by	O
activated	O
fi	O
##bro	X
##blast	X
##s	X
##12	X
##1	X
,	X
122	X
,	O
and	O
fatty	O
acids	O
may	O
be	O
supplied	O
by	O
activated	O
ad	O
##ip	X
##ocytes	X
##12	X
##3	X
,	X
124	X
.	O

Tu	O
##mour	X
and	O
s	O
##trom	X
##a	X
only	O
come	O
into	O
physical	O
contact	O
when	O
the	O
basement	O
membrane	O
is	O
breach	O
##ed	X
by	O
ma	O
##li	X
##gnant	X
neo	O
##p	X
##lastic	X
cells	O
.	O

At	O
this	O
stage	O
,	O
cancer	O
cells	O
can	O
directly	O
interact	O
with	O
cancer	O
-	X
associated	X
fi	O
##bro	X
##blast	X
##s	X
,	O
which	O
are	O
known	O
to	O
play	O
a	O
key	O
role	O
in	O
the	O
regulation	O
and	O
development	O
of	O
t	O
##umour	X
##s	X
,	O
especially	O
solid	O
t	O
##umour	X
##s	X
##12	X
##0	X
,	O
125	O
.	O

In	O
this	O
secret	O
##ory	X
reactive	O
state	O
,	O
fi	O
##bro	X
##blast	X
##s	X
facilitate	O
not	O
only	O
cancer	O
growth	O
and	O
progression	O
##12	X
##6	X
,	X
127	X
but	O
also	O
treatment	O
resistance	O
##12	X
##8	X
.	O

In	O
addition	O
,	O
their	O
presence	O
in	O
a	O
t	O
##umour	X
has	O
been	O
correlated	O
with	O
poor	O
outcomes	O
##12	X
##9	X
.	O

Other	O
resources	O
must	O
be	O
delivered	O
through	O
the	O
v	O
##as	X
##cula	X
##ture	X
.	O

Folk	O
##man	X
made	O
the	O
crucial	O
link	O
between	O
an	O
##gio	X
##genesis	X
and	O
t	O
##umour	X
invasion	O
and	O
meta	O
##sta	X
##sis	X
,	O
realizing	O
that	O
preventing	O
new	O
vessels	O
from	O
forming	O
could	O
be	O
a	O
simple	O
way	O
to	O
in	O
##hibit	X
further	O
t	O
##umour	X
growth	O
##13	X
##0	X
,	X
131	X
.	O

The	O
presence	O
in	O
many	O
t	O
##umour	X
##s	X
of	O
ne	O
##c	X
##rosis	X
and	O
h	O
##y	X
##pox	X
##ia	X
,	O
which	O
are	O
major	O
drivers	O
of	O
an	O
##gio	X
##genesis	X
,	O
at	O
##test	X
##s	X
to	O
the	O
importance	O
of	O
resource	O
limitation	O
in	O
t	O
##umour	X
##s	X
.	O

Furthermore	O
,	O
there	O
is	O
evidence	O
that	O
ne	O
##c	X
##rosis	X
is	O
a	O
pro	O
##gno	X
##stic	X
factor	O
in	O
many	O
cancer	O
##s	X
##13	X
##2	X
.	O

The	O
effects	O
of	O
resources	O
on	O
the	O
evolution	O
of	O
a	O
t	O
##umour	X
are	O
not	O
defined	O
simply	O
by	O
their	O
supply	O
,	O
de	O
##ple	X
##tion	X
and	O
availability	O
.	O

Resource	O
diversity	O
may	O
also	O
be	O
important	O
.	O

Whether	O
resources	O
are	O
uniform	O
across	O
space	O
or	O
he	O
##tero	X
##gene	X
##ous	X
(	O
‘	O
patch	X
##y	X
’	O
or	O
exhibiting	O
gradient	O
##s	X
)	O
makes	O
a	O
difference	O
##6	X
##7	X
,	X
133	X
.	O

Patch	O
##y	X
resources	O
(	O
and	O
hazards	O
)	O
create	O
multiple	O
habitats	O
(	O
for	O
example	O
,	O
rich	O
and	O
sparse	O
regions	O
)	O
that	O
may	O
select	O
for	O
different	O
clone	O
##s	X
that	O
can	O
survive	O
in	O
those	O
regions	O
and	O
may	O
be	O
differential	O
##ly	X
re	O
##sp	X
##ons	X
##ive	X
to	O
(	O
and	O
differential	O
##ly	X
exposed	O
to	O
)	O
the	O
##rap	X
##ies	X
.	O

Furthermore	O
,	O
we	O
and	O
others	O
have	O
shown	O
that	O
if	O
those	O
patch	O
##y	X
resources	O
change	O
over	O
time	O
,	O
then	O
there	O
is	O
selective	O
pressure	O
on	O
cells	O
to	O
move	O
to	O
escape	O
regions	O
of	O
scarce	O
resources	O
and	O
exploit	O
trans	O
##ient	X
regions	O
of	O
more	O
p	O
##lent	X
##iful	X
resources	O
##6	X
##7	X
,	X
113	X
,	O
114	X
,	O
134	X
–	X
136	X
.	O

Thus	O
,	O
ecological	O
theory	O
predict	O
##s	X
that	O
he	O
##tero	X
##gene	X
##ous	X
resources	O
should	O
select	O
for	O
invasion	O
and	O
meta	O
##sta	X
##sis	X
##13	X
##4	X
,	X
135	X
,	O
and	O
there	O
is	O
evidence	O
to	O
support	O
that	O
prediction	O
in	O
cancer	O
##13	X
##7	X
–	X
143	X
.	O

V	O
##erd	X
##uz	X
##co	X
and	O
colleagues	O
found	O
that	O
intermittent	O
exposure	O
of	O
some	O
cell	O
lines	O
to	O
h	O
##y	X
##pox	X
##ia	X
selected	O
for	O
increased	O
resistance	O
to	O
a	O
variety	O
of	O
ch	O
##em	X
##oth	X
##era	X
##pies	X
,	O
including	O
et	O
##op	X
##os	X
##ide	X
,	O
do	O
##ce	X
##ta	X
##xe	X
##l	X
and	O
met	O
##hot	X
##re	X
##xa	X
##te	X
,	O
compared	O
with	O
un	O
##sel	X
##ec	X
##ted	X
controls	O
##14	X
##4	X
.	O

In	O
addition	O
,	O
resource	O
gradient	O
##s	X
often	O
lead	O
to	O
rapid	O
evolution	O
,	O
as	O
organisms	O
that	O
are	O
able	O
to	O
invade	O
more	O
stress	O
##ful	X
environments	O
can	O
escape	O
competition	O
and	O
flourish	O
##14	X
##5	X
.	O

Much	O
needs	O
to	O
be	O
learned	O
about	O
resource	O
he	O
##tero	X
##gene	X
##ity	X
,	O
consumer	O
–	X
resource	X
dynamics	O
and	O
the	O
for	O
##aging	X
ecology	O
of	O
neo	O
##p	X
##lastic	X
cells	O
.	O

Me	O
##as	X
##uring	X
resources	O
Me	O
##as	X
##uring	X
resources	O
(	O
and	O
hazards	O
)	O
requires	O
the	O
consideration	O
of	O
relevant	O
spatial	O
and	O
temporal	O
scales	O
.	O

It	O
is	O
not	O
yet	O
clear	O
how	O
to	O
combine	O
measures	O
of	O
the	O
level	O
of	O
resources	O
,	O
their	O
spatial	O
variance	O
and	O
their	O
stability	O
over	O
time	O
into	O
a	O
single	O
s	O
##tat	X
##istic	X
.	O

There	O
are	O
various	O
resources	O
and	O
methods	O
to	O
measure	O
them	O
that	O
may	O
be	O
pro	O
##gno	X
##stic	X
##ally	X
relevant	O
(	O
T	O
##AB	X
##LE	X
1	O
)	O
.	O

The	O
proportion	O
of	O
a	O
t	O
##umour	X
that	O
is	O
ne	O
##c	X
##rot	X
##ic	X
or	O
poorly	O
per	O
##fused	X
may	O
be	O
read	O
from	O
standard	O
p	O
##os	X
##it	X
##ron	X
emission	O
to	O
##mo	X
##graphy	X
and	O
com	O
##puted	X
to	O
##mo	X
##graphy	X
(	O
P	O
##ET	X
–	X
CT	X
)	O
images	O
##14	X
##6	X
and	O
through	O
other	O
measures	O
of	O
blood	O
vessel	O
density	O
##14	X
##7	X
,	X
148	X
.	O

The	O
degree	O
and	O
patch	O
##iness	X
of	O
h	O
##y	X
##pox	X
##ia	X
can	O
also	O
be	O
ass	O
##ay	X
##ed	X
in	O
FF	O
##P	X
##E	X
samples	O
with	O
antibodies	O
against	O
carbon	O
##ic	X
an	O
##hy	X
##dra	X
##se	X
9	O
(	O
CA	O
##9	X
)	O
or	O
h	O
##y	X
##pox	X
##ia	X
-	X
in	X
##du	X
##cible	X
factor	O
1	O
##α	X
(	O
H	O
##IF	X
##1	X
##α	X
)	O
115	O
or	O
via	O
in	O
##tra	X
##ven	X
##ous	X
introduction	O
of	O
2	O
-	X
(	O
2	O
-	X
ni	X
##tro	X
-	X
1	X
-	X
H	X
-	X
im	X
##ida	X
##zo	X
##l	X
-	X
1	X
-	X
y	X
##l	X
)	O
-	O
N	X
-	X
(	O
2	O
,	X
2	X
,	X
3	X
,	X
3	X
,	X
3	X
-	X
pen	X
##ta	X
##f	X
##lu	X
##oro	X
##p	X
##rop	X
##yl	X
)	O
ace	O
##tam	X
##ide	X
(	O
E	O
##F	X
##5	X
)	O
and	O
the	O
subsequent	O
measurement	O
of	O
its	O
binding	O
in	O
the	O
t	O
##umour	X
tissue	O
##14	X
##9	X
.	O

E	O
##F	X
##5	X
binding	O
and	O
related	O
techniques	O
have	O
proved	O
useful	O
in	O
the	O
clinic	O
for	O
detect	O
##ing	X
regions	O
of	O
h	O
##y	X
##pox	X
##ia	X
,	O
determining	O
pro	O
##gno	X
##sis	X
and	O
measuring	O
response	O
to	O
therapy	O
##15	X
##0	X
.	O

While	O
it	O
is	O
difficult	O
to	O
measure	O
glucose	O
concentration	O
directly	O
,	O
an	O
indirect	O
measure	O
may	O
be	O
made	O
via	O
im	O
##mu	X
##no	X
##his	X
##to	X
##chemistry	X
stain	O
##ing	X
for	O
expression	O
of	O
G	B-gene
##L	X
##UT	X
##11	X
##15	X
.	O

Me	O
##asures	X
of	O
ATP	O
may	O
also	O
be	O
a	O
good	O
indirect	O
measure	O
of	O
the	O
amount	O
of	O
resources	O
available	O
to	O
neo	O
##p	X
##lastic	X
cells	O
##15	X
##1	X
.	O

G	O
##lut	X
##amine	X
,	O
p	O
##yr	X
##u	X
##vate	X
,	O
la	O
##ct	X
##ate	X
,	O
fatty	O
acids	O
,	O
calcium	O
,	O
potassium	O
,	O
p	O
##hos	X
##phorus	X
and	O
various	O
trace	O
metals	O
may	O
also	O
be	O
limiting	O
and	O
important	O
to	O
measure	O
,	O
but	O
this	O
appears	O
to	O
be	O
une	O
##x	X
##p	X
##lore	X
##d	X
.	O

Most	O
of	O
these	O
measures	O
will	O
be	O
limited	O
to	O
bio	O
##psy	X
samples	O
anal	O
##ys	X
##ed	X
ex	O
v	O
##ivo	X
and	O
thus	O
will	O
suffer	O
the	O
problems	O
of	O
spatial	O
he	O
##tero	X
##gene	X
##ity	X
and	O
sampling	O
error	O
.	O

In	O
some	O
cases	O
,	O
the	O
problem	O
of	O
spatial	O
he	O
##tero	X
##gene	X
##ity	X
and	O
sampling	O
error	O
can	O
be	O
avoided	O
through	O
gross	O
measures	O
of	O
resources	O
from	O
radio	O
##logical	X
images	O
##15	X
##2	X
–	X
154	X
Radio	O
##graphic	X
images	O
such	O
as	O
those	O
obtained	O
using	O
P	O
##ET	X
–	X
CT	X
and	O
magnetic	O
resonance	O
imaging	O
(	O
MR	O
##I	X
)	O
can	O
provide	O
valuable	O
habitat	O
data	O
.	O

In	O
natural	O
systems	O
,	O
there	O
is	O
usually	O
a	O
tight	O
correlation	O
between	O
habitat	O
and	O
the	O
types	O
and	O
characteristics	O
of	O
species	O
inhabit	O
##ing	X
the	O
habitat	O
.	O

Similarly	O
,	O
simply	O
knowing	O
the	O
different	O
habitat	O
types	O
within	O
a	O
t	O
##umour	X
may	O
be	O
pro	O
##gno	X
##stic	X
of	O
the	O
community	O
of	O
cancer	O
cells	O
and	O
therapeutic	O
outcomes	O
.	O

For	O
instance	O
,	O
in	O
g	B-disease
##lio	X
##blast	X
##oma	X
,	O
measures	O
of	O
fluid	O
-	X
at	X
##ten	X
##uated	X
in	O
##version	X
recovery	O
(	O
FL	O
##A	X
##IR	X
)	O
,	O
T	O
##1	X
and	O
T	O
##2	X
from	O
MR	O
##I	X
examinations	O
after	O
g	O
##ado	X
##lini	X
##um	X
administration	O
identified	O
distinct	O
habitats	O
that	O
correlated	O
with	O
therapeutic	O
outcome	O
,	O
independent	O
of	O
t	O
##umour	X
size	O
##15	X
##3	X
.	O

Text	O
##ure	X
analysis	O
of	O
MR	O
##I	X
scan	O
##s	X
has	O
been	O
used	O
to	O
identify	O
spatial	O
he	O
##tero	X
##gene	X
##ity	X
and	O
regional	O
variations	O
that	O
are	O
associated	O
with	O
micro	O
##en	X
##vir	X
##on	X
##mental	X
conditions	O
,	O
including	O
cell	O
density	O
,	O
tissue	O
stiff	O
##ness	X
,	O
blood	O
flow	O
and	O
nut	O
##rient	X
di	O
##sper	X
##sion	X
##15	X
##2	X
,	X
154	X
.	O

These	O
may	O
also	O
be	O
used	O
to	O
measure	O
functional	O
diversity	O
(	O
D	O
)	O
in	O
t	O
##umour	X
##s	X
.	O

Geographic	O
information	O
systems	O
(	O
G	O
##IS	X
)	O
155	O
–	X
157	X
and	O
ecology	O
##15	X
##8	X
provide	O
a	O
rich	O
literature	O
and	O
a	O
source	O
of	O
tools	O
for	O
anal	O
##ys	X
##ing	X
spatial	O
resource	O
information	O
,	O
but	O
these	O
are	O
rarely	O
utilized	O
in	O
cancer	O
research	O
##7	X
##3	X
,	O
74	O
.	O

Standard	O
his	O
##top	X
##ath	X
##ology	X
can	O
provide	O
measures	O
of	O
T	O
cell	O
in	O
##fi	X
##ltration	X
and	O
vascular	O
and	O
l	O
##ymph	X
##atic	X
density	O
##7	X
##7	X
.	O

Using	O
digital	O
path	O
##ology	X
,	O
Lloyd	O
et	O
al	O
.	O

investigated	O
the	O
spatial	O
distributions	O
of	O
o	O
##est	X
##rogen	X
receptor	O
(	O
ER	O
)	O
expression	O
in	O
relation	O
to	O
vascular	O
density	O
and	O
tissue	O
ne	O
##c	X
##rosis	X
in	O
breast	B-disease
cancer	I-disease
his	O
##tology	X
specimens	O
,	O
revealing	O
considerable	O
regional	O
variations	O
in	O
cancer	O
proliferation	O
p	O
##hen	X
##otype	X
##s	X
accompanied	O
by	O
vascular	O
##ity	X
and	O
immune	O
response	O
##11	X
##5	X
,	X
159	X
.	O

Yuan	O
and	O
colleagues	O
also	O
used	O
digital	O
path	O
##ology	X
to	O
anal	O
##ys	X
##e	X
the	O
spatial	O
relationships	O
between	O
fi	O
##bro	X
##blast	X
##s	X
and	O
neo	O
##p	X
##lastic	X
cells	O
##16	X
##0	X
.	O

We	O
have	O
summarized	O
the	O
statistics	O
and	O
ass	O
##ays	X
for	O
measuring	O
diversity	O
,	O
change	O
over	O
time	O
,	O
hazards	O
and	O
resources	O
in	O
T	O
##AB	X
##LE	X
1	O
.	O

Cat	O
##ego	X
##ries	X
of	O
t	O
##umour	X
##s	X
The	O
future	O
behaviour	O
of	O
a	O
t	O
##umour	X
depends	O
on	O
both	O
its	O
evolutionary	O
potential	O
(	O
the	O
E	O
##vo	X
-	X
index	X
)	O
and	O
the	O
selective	O
pressures	O
on	O
the	O
t	O
##umour	X
(	O
the	O
E	O
##co	X
-	X
index	X
)	O
.	O

A	O
highly	O
e	O
##vo	X
##l	X
##vable	X
t	O
##umour	X
may	O
or	O
may	O
not	O
evolve	O
immune	O
e	O
##vas	X
##ion	X
depending	O
on	O
whether	O
the	O
immune	O
system	O
is	O
imposing	O
a	O
strong	O
selective	O
pressure	O
on	O
the	O
t	O
##umour	X
.	O

By	O
contrast	O
,	O
an	O
immune	O
response	O
may	O
or	O
may	O
not	O
lead	O
to	O
immune	O
e	O
##vas	X
##ion	X
depending	O
on	O
the	O
e	O
##vo	X
##l	X
##va	X
##bility	X
of	O
the	O
t	O
##umour	X
.	O

Thus	O
,	O
both	O
the	O
evolution	O
and	O
ecology	O
of	O
a	O
t	O
##umour	X
must	O
be	O
considered	O
in	O
predict	O
##ing	X
cancer	O
outcomes	O
.	O

We	O
therefore	O
propose	O
to	O
combine	O
the	O
E	O
##vo	X
-	X
and	O
E	O
##co	X
-	X
in	X
##dices	X
to	O
class	O
##ify	X
t	O
##umour	X
##s	X
.	O

Di	O
##cho	X
##tom	X
##izing	X
each	O
evolutionary	O
and	O
ecological	O
factor	O
of	O
the	O
E	O
##vo	X
-	X
and	O
E	O
##co	X
-	X
in	X
##dices	X
into	O
high	O
and	O
low	O
values	O
would	O
produce	O
16	O
possible	O
types	O
of	O
t	O
##umour	X
(	O
T	O
##AB	X
##LE	X
2	O
)	O
.	O

In	O
order	O
to	O
class	O
##ify	X
a	O
t	O
##umour	X
,	O
investigators	O
will	O
first	O
need	O
to	O
define	O
and	O
valid	O
##ate	X
clinical	O
##ly	X
relevant	O
threshold	O
##s	X
for	O
di	O
##cho	X
##tom	X
##izing	X
diversity	O
,	O
change	O
over	O
time	O
,	O
hazards	O
and	O
resources	O
(	O
T	O
##AB	X
##LE	X
1	O
)	O
.	O

For	O
example	O
,	O
in	O
Barrett	B-disease
o	I-disease
##es	X
##op	X
##ha	X
##gus	X
,	O
Male	O
##y	X
and	O
colleagues	O
found	O
that	O
the	O
upper	O
q	O
##ua	X
##rt	X
##ile	X
of	O
diversity	O
statistics	O
distinguished	O
patients	B-species
who	O
are	O
likely	O
to	O
progress	O
to	O
o	B-disease
##es	X
##op	X
##hage	X
##al	X
ad	O
##eno	X
##car	X
##cin	X
##oma	X
##12	X
–	X
14	X
.	O

Once	O
those	O
threshold	O
##s	X
are	O
valid	O
##ated	X
,	O
a	O
t	O
##umour	X
would	O
be	O
measured	O
for	O
each	O
of	O
the	O
four	O
evolutionary	O
and	O
ecological	O
factors	O
to	O
determine	O
which	O
of	O
the	O
16	O
types	O
it	O
falls	O
into	O
.	O

For	O
example	O
,	O
if	O
a	O
t	O
##umour	X
was	O
below	O
the	O
threshold	O
##s	X
for	O
all	O
four	O
factors	O
(	O
that	O
is	O
,	O
a	O
D	O
##1	X
##Δ	X
##1	X
##H1	X
##R	X
##1	X
t	O
##umour	X
)	O
,	O
it	O
would	O
be	O
a	O
type	O
1	O
t	O
##umour	X
.	O

A	O
road	O
##ma	X
##p	X
for	O
improvements	O
We	O
are	O
not	O
yet	O
in	O
a	O
position	O
to	O
specify	O
which	O
measures	O
and	O
threshold	O
##s	X
should	O
be	O
used	O
to	O
determine	O
the	O
D	O
#	O
Δ	O
#	O
or	O
H	O
#	O
R	O
#	O
type	O
of	O
a	O
t	O
##umour	X
.	O

Initial	O
studies	O
should	O
test	O
if	O
these	O
classification	O
##s	X
significantly	O
predict	O
clinical	O
outcomes	O
and	O
which	O
evolutionary	O
and	O
ecological	O
measures	O
provide	O
independent	O
predict	O
##ive	X
value	O
.	O

They	O
should	O
also	O
test	O
if	O
there	O
are	O
measures	O
that	O
can	O
apply	O
across	O
cancer	O
types	O
or	O
if	O
they	O
have	O
to	O
be	O
uniquely	O
defined	O
for	O
specific	O
organs	O
or	O
t	O
##umour	X
sub	O
##type	X
##s	X
.	O

Future	O
studies	O
should	O
test	O
alternative	O
measures	O
of	O
diversity	O
,	O
change	O
over	O
time	O
(	O
B	O
##OX	X
2	O
)	O
,	O
hazards	O
and	O
resources	O
to	O
help	O
standard	O
##ize	X
useful	O
metric	O
##s	X
for	O
the	O
classification	O
##s	X
.	O

They	O
should	O
also	O
q	O
##uant	X
##ify	X
the	O
improvements	O
to	O
pro	O
##gno	X
##sis	X
gained	O
by	O
sampling	O
multiple	O
regions	O
at	O
multiple	O
time	O
##points	X
.	O

The	O
future	O
of	O
the	O
E	O
##vo	X
-	X
index	X
Our	O
framework	O
for	O
q	O
##uant	X
##ifying	X
the	O
e	O
##vo	X
##l	X
##va	X
##bility	X
of	O
a	O
neo	O
##p	X
##las	X
##m	X
is	O
based	O
on	O
the	O
diversity	O
within	O
the	O
t	O
##umour	X
and	O
how	O
that	O
diversity	O
changes	O
over	O
time	O
.	O

Di	O
##versity	X
and	O
genetic	O
change	O
over	O
time	O
are	O
the	O
easily	O
o	O
##bs	X
##er	X
##vable	X
results	O
of	O
the	O
underlying	O
evolutionary	O
dynamics	O
.	O

A	O
future	O
evolutionary	O
index	O
(	O
E	O
##vo	X
-	X
index	X
)	O
may	O
be	O
based	O
on	O
the	O
parameters	O
that	O
determine	O
the	O
rates	O
of	O
evolution	O
##15	X
:	O
Mu	O
##tation	X
rate	O
##17	X
,	X
178	X
Population	O
size	O
of	O
the	O
self	O
-	X
renew	X
##ing	X
neo	O
##p	X
##lastic	X
cells	O
(	O
also	O
known	O
as	O
‘	O
cancer	O
stem	O
cells	O
’	O
)	O
,	O
which	O
are	O
the	O
units	O
of	O
evolutionary	O
selection	O
in	O
cancer	O
##3	X
Generation	O
time	O
of	O
the	O
self	O
-	X
renew	X
##ing	X
neo	O
##p	X
##lastic	X
cells	O
Select	O
##ive	X
coefficients	O
##17	X
,	X
179	X
or	O
c	O
##lon	X
##al	X
expansion	O
rates	O
##14	X
Her	O
##ita	X
##bility	X
of	O
selective	O
##ly	X
advantage	O
##ous	X
p	O
##hen	X
##otype	X
##s	X
Most	O
of	O
these	O
parameters	O
are	O
currently	O
difficult	O
to	O
measure	O
.	O

However	O
,	O
there	O
is	O
already	O
good	O
evidence	O
that	O
the	O
number	O
of	O
self	O
-	X
renew	X
##ing	X
cells	O
in	O
a	O
t	O
##umour	X
is	O
associated	O
with	O
adverse	O
outcomes	O
##18	X
##0	X
,	X
181	X
,	O
that	O
self	O
-	X
renew	X
##ing	X
cell	O
frequency	O
increases	O
with	O
progression	O
##18	X
##2	X
,	X
183	X
and	O
that	O
self	O
-	X
renewal	X
signalling	O
pathways	O
are	O
action	O
##able	X
and	O
effective	O
targets	O
for	O
therapy	O
##18	X
##4	X
,	X
185	X
.	O

This	O
is	O
probably	O
true	O
for	O
all	O
types	O
of	O
t	O
##umour	X
.	O

As	O
##say	X
##ing	X
self	O
-	X
renew	X
##ing	X
cells	O
functional	O
##ly	X
(	O
by	O
x	O
##eno	X
##tra	X
##ns	X
##p	X
##lant	X
##ation	X
)	O
is	O
difficult	O
,	O
but	O
q	O
##uant	X
##ifying	X
stem	O
cell	O
signatures	O
is	O
possible	O
.	O

However	O
,	O
stem	O
cell	O
p	O
##hen	X
##otype	X
##s	X
are	O
not	O
stable	O
and	O
can	O
be	O
m	O
##od	X
##ulated	X
both	O
by	O
genetic	O
changes	O
and	O
(	O
e	O
##pi	X
##gene	X
##tically	X
)	O
by	O
ecological	O
conditions	O
(	O
for	O
example	O
,	O
h	O
##y	X
##pox	X
##ia	X
)	O
3	O
,	O
suggesting	O
that	O
the	O
importance	O
of	O
any	O
one	O
parameter	O
is	O
also	O
a	O
function	O
of	O
its	O
her	O
##ita	X
##bility	X
.	O

The	O
ecology	O
of	O
a	O
t	O
##umour	X
affects	O
its	O
evolution	O
,	O
and	O
the	O
evolution	O
of	O
the	O
cells	O
in	O
a	O
t	O
##umour	X
change	O
their	O
ecology	O
.	O

Neo	O
##p	X
##lastic	X
cells	O
evolve	O
g	O
##eno	X
##mic	X
instability	O
##16	X
##1	X
,	O
generating	O
neo	O
-	X
anti	X
##gens	X
as	O
well	O
as	O
adaptations	O
,	O
such	O
as	O
recruitment	O
of	O
resources	O
,	O
through	O
act	O
##ivating	X
fi	O
##bro	X
##blast	X
##s	X
##16	X
##2	X
and	O
neo	O
-	X
an	X
##gio	X
##genesis	X
##16	X
##1	X
.	O

Evolution	O
of	O
neo	O
-	X
anti	X
##gens	X
trigger	O
##s	X
immune	O
pre	O
##dation	X
,	O
which	O
may	O
reduce	O
diversity	O
and	O
select	O
for	O
immune	O
e	O
##vas	X
##ion	X
##16	X
##3	X
.	O

High	O
levels	O
of	O
ex	O
##tri	X
##ns	X
##ic	X
mortality	O
and	O
resources	O
select	O
for	O
rapid	O
proliferation	O
with	O
little	O
investment	O
in	O
so	O
##matic	X
maintenance	O
##7	X
##1	X
.	O

These	O
interactions	O
imply	O
that	O
not	O
all	O
possible	O
combinations	O
of	O
ecological	O
and	O
evolutionary	O
measurements	O
are	O
equally	O
likely	O
.	O

We	O
will	O
probably	O
be	O
able	O
to	O
drop	O
some	O
of	O
the	O
16	O
possible	O
t	O
##umour	X
types	O
in	O
T	O
##AB	X
##LE	X
2	O
and	O
focus	O
on	O
the	O
subset	O
of	O
classes	O
that	O
present	O
in	O
the	O
clinic	O
.	O

The	O
framework	O
for	O
a	O
classification	O
system	O
that	O
we	O
have	O
proposed	O
could	O
be	O
incorporated	O
into	O
clinical	O
trials	O
,	O
which	O
could	O
allow	O
us	O
to	O
gather	O
data	O
on	O
how	O
the	O
different	O
types	O
of	O
evolving	O
t	O
##umour	X
respond	O
to	O
different	O
types	O
of	O
intervention	O
(	O
F	O
##IG	X
.	O

4	O
)	O
.	O

Clinical	O
trials	O
could	O
then	O
be	O
developed	O
to	O
s	O
##tra	X
##ti	X
##fy	X
treatment	O
of	O
patients	B-species
based	O
on	O
the	O
E	O
##vo	X
-	X
and	O
E	O
##co	X
-	X
in	X
##dices	X
of	O
their	O
t	O
##umour	X
##s	X
.	O

We	O
could	O
use	O
the	O
results	O
to	O
develop	O
guidelines	O
for	O
best	O
practice	O
in	O
managing	O
cancer	O
##s	X
.	O

Vision	O
of	O
the	O
future	O
In	O
the	O
future	O
,	O
the	O
path	O
##ology	X
report	O
for	O
a	O
neo	O
##p	X
##las	X
##m	X
could	O
include	O
its	O
E	O
##vo	X
-	X
index	X
and	O
E	O
##co	X
-	X
index	X
classification	O
##s	X
.	O

I	O
##dea	X
##lly	X
,	O
these	O
classification	O
##s	X
would	O
provide	O
‘	O
chess	X
##board	X
’	X
-	X
like	X
scenarios	O
where	O
,	O
based	O
on	O
the	O
current	O
evolutionary	O
class	O
of	O
a	O
t	O
##umour	X
,	O
one	O
could	O
anti	O
##ci	X
##pate	X
how	O
the	O
t	O
##umour	X
type	O
will	O
change	O
with	O
different	O
possible	O
therapeutic	O
moves	O
(	O
F	O
##IG	X
.	O

4	O
)	O
.	O

Clinic	O
##ians	X
would	O
then	O
be	O
able	O
to	O
choose	O
appropriate	O
interventions	O
for	O
the	O
e	O
##vo	X
##l	X
##va	X
##bility	X
of	O
those	O
neo	O
##p	X
##las	X
##ms	X
and	O
would	O
also	O
be	O
able	O
to	O
track	O
whether	O
the	O
neo	O
##p	X
##las	X
##ms	X
change	O
substantially	O
in	O
response	O
to	O
interventions	O
.	O

A	O
D	O
##1	X
##Δ	X
##1	X
t	O
##umour	X
or	O
even	O
a	O
D	O
##1	X
##Δ	X
##2	X
t	O
##umour	X
would	O
be	O
a	O
prime	O
candidate	O
for	O
aggressive	O
therapy	O
with	O
cu	O
##rative	X
intent	O
.	O

In	O
fact	O
,	O
a	O
D	O
##1	X
##Δ	X
##1	X
t	O
##umour	X
may	O
be	O
so	O
evolution	O
##arily	X
in	O
##do	X
##lent	X
as	O
to	O
not	O
require	O
any	O
form	O
of	O
intervention	O
.	O

On	O
the	O
other	O
hand	O
,	O
a	O
D	O
##2	X
##Δ	X
##2	X
t	O
##umour	X
is	O
likely	O
to	O
have	O
multiple	O
resistant	O
sub	O
-	X
clone	X
##s	X
present	O
at	O
diagnosis	O
,	O
and	O
future	O
clinical	O
trials	O
should	O
test	O
if	O
such	O
a	O
t	O
##umour	X
can	O
be	O
managed	O
through	O
strategies	O
that	O
minimize	O
the	O
expansion	O
of	O
resistant	O
sub	O
-	X
clone	X
##s	X
by	O
exploit	O
##ing	X
their	O
disadvantage	O
in	O
competition	O
with	O
sensitive	O
sub	O
##c	X
##lone	X
##s	X
##16	X
##4	X
.	O

A	O
legitimate	O
clinical	O
strategy	O
might	O
be	O
to	O
down	O
-	X
stage	X
a	O
t	O
##umour	X
from	O
a	O
highly	O
e	O
##vo	X
##l	X
##vable	X
one	O
to	O
a	O
much	O
more	O
clinical	O
##ly	X
manage	O
##able	X
class	O
that	O
could	O
be	O
contained	O
in	O
a	O
non	O
-	X
lethal	X
state	O
indefinitely	O
(	O
F	O
##IG	X
.	O

4	O
##b	X
)	O
.	O

If	O
valid	O
##ated	X
,	O
the	O
E	O
##vo	X
-	X
and	O
E	O
##co	X
-	X
in	X
##dices	X
could	O
be	O
used	O
as	O
sur	O
##rogate	X
measures	O
for	O
overall	O
survival	O
or	O
disease	O
-	X
free	X
survival	O
.	O

Con	O
##c	X
##lusion	X
##s	X
The	O
evolutionary	O
biology	O
of	O
cancer	O
is	O
,	O
clinical	O
##ly	X
,	O
in	O
a	O
similar	O
state	O
to	O
ps	O
##ych	X
##ia	X
##try	X
in	O
the	O
nineteenth	O
century	O
.	O

At	O
that	O
time	O
,	O
there	O
was	O
no	O
standard	O
classification	O
system	O
for	O
mental	B-disease
illness	I-disease
used	O
by	O
practitioners	O
.	O

Without	O
such	O
a	O
classification	O
system	O
,	O
it	O
was	O
difficult	O
to	O
even	O
talk	O
about	O
the	O
illness	O
,	O
let	O
alone	O
make	O
progress	O
,	O
as	O
a	O
common	O
language	O
was	O
lacking	O
.	O

With	O
the	O
American	O
Medical	O
Association	O
’	O
s	X
Standard	O
Class	O
##ified	X
No	O
##menclature	X
of	O
Disease	O
published	O
in	O
1933	O
(	O
R	O
##EF	X
.	O

165	O
)	O
and	O
the	O
first	O
Di	O
##ag	X
##nos	X
##tic	X
and	O
Statistical	O
Manual	O
of	O
Mental	O
Di	O
##sor	X
##ders	X
published	O
in	O
1952	O
(	O
R	O
##EF	X
.	O

166	O
)	O
,	O
no	O
matter	O
how	O
fl	O
##awed	X
they	O
were	O
,	O
di	O
##ag	X
##nose	X
##s	X
of	O
mental	B-disease
disorders	I-disease
became	O
standardized	O
,	O
which	O
facilitated	O
studies	O
to	O
re	O
##fine	X
both	O
the	O
classification	O
##s	X
as	O
well	O
as	O
the	O
treatment	O
of	O
those	O
disorders	O
.	O

Studies	O
based	O
on	O
the	O
same	O
classification	O
system	O
were	O
then	O
comparable	O
,	O
which	O
further	O
facilitated	O
meta	O
-	X
analyses	X
and	O
overall	O
progress	O
in	O
the	O
field	O
.	O

We	O
have	O
diagnostic	O
categories	O
for	O
types	O
of	O
t	O
##umour	X
based	O
on	O
their	O
tissue	O
of	O
origin	O
and	O
staging	O
,	O
as	O
well	O
as	O
some	O
molecular	O
markers	O
,	O
but	O
we	O
have	O
lacked	O
a	O
system	O
for	O
class	O
##ifying	X
the	O
e	O
##vo	X
##l	X
##va	X
##bility	X
and	O
ecology	O
of	O
a	O
t	O
##umour	X
,	O
which	O
help	O
determine	O
how	O
it	O
will	O
respond	O
to	O
interventions	O
and	O
how	O
it	O
might	O
best	O
be	O
managed	O
.	O

Evolution	O
##ary	X
on	O
##cology	X
requires	O
a	O
shared	O
le	O
##xi	X
##con	X
upon	O
which	O
to	O
base	O
discovery	O
.	O

We	O
reached	O
consensus	O
on	O
the	O
proposed	O
framework	O
for	O
a	O
classification	O
system	O
to	O
character	O
##ize	X
evolutionary	O
differences	O
between	O
t	O
##umour	X
##s	X
that	O
is	O
applicable	O
across	O
all	O
cancer	O
types	O
.	O

Important	O
##ly	X
,	O
an	O
evolutionary	O
classification	O
system	O
will	O
facilitate	O
future	O
efforts	O
to	O
study	O
this	O
fundamental	O
property	O
of	O
t	O
##umour	X
##s	X
to	O
reveal	O
implications	O
for	O
treatment	O
.	O

C	O
##lon	X
##al	X
evolution	O
in	O
cancer	B-disease
Cancer	O
genome	O
landscapes	O
Evolution	O
##ary	X
de	O
##ter	X
##mina	X
##nts	X
of	O
cancer	B-disease
The	O
c	O
##lon	X
##al	X
evolution	O
of	O
tumor	B-disease
cell	O
populations	O
High	O
in	O
##tra	X
##tum	X
##or	X
genetic	O
he	O
##tero	X
##gene	X
##ity	X
is	O
related	O
to	O
worse	O
outcome	O
in	O
patients	B-species
with	O
head	B-disease
and	I-disease
neck	I-disease
sq	I-disease
##ua	X
##mous	X
cell	I-disease
car	I-disease
##cin	X
##oma	X
Pan	B-disease
-	X
cancer	X
analysis	O
of	O
the	O
extent	O
and	O
consequences	O
of	O
in	O
##tra	X
##tum	X
##or	X
he	O
##tero	X
##gene	X
##ity	X
Ph	O
##yl	X
##ogen	X
##etic	X
analysis	O
of	O
multiple	O
F	O
##IS	X
##H	X
markers	O
in	O
oral	B-disease
tongue	I-disease
sq	I-disease
##ua	X
##mous	X
cell	I-disease
car	I-disease
##cin	X
##oma	X
suggests	O
that	O
a	O
diverse	O
distribution	O
of	O
copy	O
number	O
changes	O
is	O
associated	O
with	O
poor	O
pro	O
##gno	X
##sis	X
Spa	O
##tial	X
and	O
temporal	O
he	O
##tero	X
##gene	X
##ity	X
in	O
high	O
-	X
grade	X
se	B-disease
##rous	X
o	I-disease
##var	X
##ian	X
cancer	I-disease
:	O
a	O
phylogenetic	O
analysis	O
C	O
##lon	X
##al	X
c	O
##yt	X
##ogen	X
##etic	X
progression	O
within	O
in	O
##tra	X
##tum	X
##oral	X
##ly	X
he	O
##tero	X
##gene	X
##ous	X
men	B-disease
##ing	X
##io	X
##mas	X
predict	O
##s	X
tumor	O
re	O
##cu	X
##rrence	X
Para	O
##dox	X
##ical	X
relationship	O
between	O
ch	O
##rom	X
##oso	X
##mal	X
instability	O
and	O
survival	O
outcome	O
in	O
cancer	O
Relations	O
##hip	X
of	O
extreme	O
ch	O
##rom	X
##oso	X
##mal	X
instability	O
with	O
long	O
-	X
term	X
survival	O
in	O
a	O
retrospective	O
analysis	O
of	O
primary	O
breast	B-disease
cancer	I-disease
Gene	O
##tic	X
c	O
##lon	X
##al	X
diversity	O
predict	O
##s	X
progression	O
to	O
es	B-disease
##op	X
##hage	X
##al	X
ad	I-disease
##eno	X
##car	X
##cin	X
##oma	X
A	O
comprehensive	O
survey	O
of	O
c	O
##lon	X
##al	X
diversity	O
measures	O
in	O
bar	O
##ret	X
##t	X
’	O
s	X
es	O
##op	X
##ha	X
##gus	X
as	O
bio	O
##mark	X
##ers	X
of	O
progression	O
to	O
es	B-disease
##op	X
##hage	X
##al	X
ad	I-disease
##eno	X
##car	X
##cin	X
##oma	X
D	O
##ynamic	X
c	O
##lon	X
##al	X
equilibrium	O
and	O
pre	O
##det	X
##ermined	X
cancer	O
risk	O
in	O
Barrett	B-disease
’	I-disease
s	X
o	I-disease
##es	X
##op	X
##ha	X
##gus	X
Cancer	I-disease
evolution	O
and	O
the	O
limits	O
of	O
predict	O
##ability	X
in	O
precision	O
cancer	B-disease
medicine	O
Pan	O
-	X
cancer	X
analysis	O
of	O
in	O
##tra	X
##tum	X
##or	X
he	O
##tero	X
##gene	X
##ity	X
as	O
a	O
pro	O
##gno	X
##stic	X
de	O
##ter	X
##mina	X
##nt	X
of	O
survival	O
I	O
##dent	X
##ification	X
of	O
neutral	O
tumor	O
evolution	O
across	O
cancer	O
types	O
In	O
##fer	X
##ring	X
the	O
origin	O
of	O
meta	O
##sta	X
##ses	X
from	O
cancer	B-disease
p	O
##hyl	X
##ogen	X
##ies	X
Analysis	O
of	O
circulating	O
tumor	O
DNA	O
to	O
monitor	O
meta	O
##static	X
breast	B-disease
cancer	I-disease
Cancer	O
evolution	O
:	O
mathematical	O
models	O
and	O
computational	O
in	O
##ference	X
Impact	O
of	O
del	O
##eter	X
##ious	X
passenger	O
mutations	O
on	O
cancer	O
progression	O
Tu	O
##g	X
-	X
of	X
-	X
war	X
between	O
driver	O
and	O
passenger	O
mutations	O
in	O
cancer	O
and	O
other	O
adaptive	O
processes	O
Evolution	O
of	O
cooperation	O
among	O
tumor	O
cells	O
Non	O
-	X
cell	X
-	X
autonomous	X
driving	O
of	O
t	B-disease
##umour	X
growth	O
supports	O
sub	O
-	X
c	X
##lon	X
##al	X
he	O
##tero	X
##gene	X
##ity	X
In	O
##tra	X
-	X
t	X
##umour	X
he	O
##tero	X
##gene	X
##ity	X
:	O
a	O
looking	O
glass	O
for	O
cancer	O
?	O

He	O
##tero	X
##gene	X
##ous	X
tumor	O
sub	O
##pop	X
##ulation	X
##s	X
cooperate	O
to	O
drive	O
invasion	O
Tu	O
##mour	X
cell	O
he	O
##tero	X
##gene	X
##ity	X
maintained	O
by	O
co	O
##oper	X
##ating	X
sub	O
##c	X
##lone	X
##s	X
in	O
W	O
##nt	X
-	X
driven	X
ma	B-disease
##mma	X
##ry	X
cancer	I-disease
##s	X
Theory	O
for	O
the	O
evolution	O
of	O
di	O
##ff	X
##us	X
##ible	X
external	O
goods	O
Toward	O
understanding	O
and	O
exploit	O
##ing	X
tumor	O
he	O
##tero	X
##gene	X
##ity	X
Evolution	O
and	O
measurement	O
of	O
species	O
diversity	O
Cell	O
##ular	X
and	O
genetic	O
diversity	O
in	O
the	O
progression	O
of	O
in	O
sit	O
##u	X
human	B-species
breast	B-disease
car	I-disease
##cin	X
##oma	X
##s	X
to	O
an	O
invasive	O
p	O
##hen	X
##otype	X
In	O
##tra	X
-	X
tumor	X
genetic	O
he	O
##tero	X
##gene	X
##ity	X
and	O
mortality	O
in	O
head	B-disease
and	I-disease
neck	I-disease
cancer	I-disease
:	O
analysis	O
of	O
data	O
from	O
the	O
Cancer	O
Gen	O
##ome	X
Atlas	O
Un	O
##i	X
##F	X
##rac	X
:	O
an	O
effective	O
distance	O
metric	O
for	O
micro	O
##bial	X
community	O
comparison	O
Se	O
##quence	X
diver	O
##gence	X
,	O
functional	O
con	O
##stra	X
##int	X
,	O
and	O
selection	O
in	O
protein	O
evolution	O
Contemporary	O
g	O
##lea	X
##son	X
g	O
##rading	X
of	O
pro	B-disease
##static	X
car	I-disease
##cin	X
##oma	X
:	O
an	O
update	O
with	O
discussion	O
on	O
practical	O
issues	O
to	O
implement	O
the	O
2014	O
international	O
society	O
of	O
u	O
##rol	X
##ogical	X
path	O
##ology	X
(	O
IS	O
##UP	X
)	O
consensus	O
conference	O
on	O
g	O
##lea	X
##son	X
g	O
##rading	X
of	O
pro	B-disease
##static	X
car	I-disease
##cin	X
##oma	X
EA	O
##U	X
guidelines	O
on	O
non	B-disease
-	X
muscle	X
-	X
invasive	X
u	I-disease
##roth	X
##eli	X
##al	X
car	I-disease
##cin	X
##oma	X
of	I-disease
the	I-disease
bladder	I-disease
:	O
update	O
2013	O
AC	O
##G	X
Clinical	O
Guide	O
##line	X
:	O
Di	O
##ag	X
##nosis	X
and	O
management	O
of	O
Barrett	B-disease
’	I-disease
s	X
es	I-disease
##op	X
##ha	X
##gus	X
Ph	O
##yl	X
##ogen	X
##etic	X
c	O
##t	X
##D	X
##NA	X
analysis	O
depicts	O
early	O
-	X
stage	X
lung	B-disease
cancer	I-disease
evolution	O
C	O
##lon	X
##al	X
evolution	O
of	O
g	B-disease
##lio	X
##blast	X
##oma	X
under	O
therapy	O
Sign	O
##ature	X
##s	X
of	O
mutation	O
##al	X
processes	O
in	O
human	B-species
cancer	O
Bay	O
##esi	X
##an	X
molecular	O
clock	O
dating	O
of	O
species	O
diver	O
##gence	X
##s	X
in	O
the	O
g	O
##eno	X
##mic	X
##s	X
era	O
Mass	O
##ive	X
g	O
##eno	X
##mic	X
rear	O
##rang	X
##ement	X
acquired	O
in	O
a	O
single	O
catastrophic	O
event	O
during	O
cancer	O
development	O
Di	O
##verse	X
system	O
stresses	O
:	O
common	O
mechanisms	O
of	O
chromosome	O
fragment	O
##ation	X
To	O
##ler	X
##ance	X
of	O
whole	O
-	X
genome	X
doubling	O
prop	O
##aga	X
##tes	X
ch	O
##rom	X
##oso	X
##mal	X
instability	O
and	O
accelerate	O
##s	X
cancer	B-disease
genome	O
evolution	O
Te	O
##mpo	X
##ral	X
and	O
spatial	O
evolution	O
of	O
so	O
##matic	X
ch	O
##rom	X
##oso	X
##mal	X
alterations	O
:	O
a	O
case	O
-	X
co	X
##hor	X
##t	X
study	O
of	O
Barrett	B-disease
’	I-disease
s	X
es	I-disease
##op	X
##ha	X
##gus	X
The	O
proper	O
place	O
of	O
hopeful	O
monsters	O
in	O
evolutionary	O
biology	O
Human	B-species
cancer	O
##s	X
express	O
a	O
m	O
##uta	X
##tor	X
p	O
##hen	X
##otype	X
:	O
hypothesis	O
,	O
origin	O
,	O
and	O
consequences	O
DNA	O
repair	O
,	O
genome	O
stability	O
and	O
cancer	O
:	O
a	O
historical	O
perspective	O
Det	O
##ec	X
##tion	X
of	O
u	O
##bi	X
##quito	X
##us	X
and	O
he	O
##tero	X
##gene	X
##ous	X
mutations	O
in	O
cell	O
-	X
free	X
DNA	O
from	O
patients	B-species
with	O
early	O
-	X
stage	X
non	B-disease
-	X
small	X
-	X
cell	X
lung	I-disease
cancer	I-disease
The	O
accumulation	O
of	O
del	O
##eter	X
##ious	X
genes	O
in	O
a	O
population	O
-	X
Muller	X
’	O
s	X
Rat	O
##chet	X
Me	O
##as	X
##ura	X
##bly	X
evolving	O
populations	O
Op	O
##ti	X
##mi	X
##zation	X
of	O
dos	O
##ing	X
for	O
E	O
##G	X
##F	X
##R	X
-	X
mutant	X
non	B-disease
-	X
small	X
cell	I-disease
lung	I-disease
cancer	I-disease
with	O
evolutionary	O
cancer	O
modeling	O
Select	O
##ively	X
advantage	O
##ous	X
mutations	O
and	O
hit	O
##ch	X
##hi	X
##kers	X
in	O
neo	O
##p	X
##las	X
##ms	X
:	O
p	B-gene
##16	X
lesions	O
are	O
selected	O
in	O
Barrett	B-disease
’	X

Aug	O
##mentation	X
of	O
the	O
cu	O
##rative	X
effect	O
of	O
met	O
##hyl	X
##gly	X
##ox	X
##al	X
on	O
cancer	O
-	X
bearing	X
mice	B-species
by	O
as	O
##cor	X
##bic	X
acid	O
and	O
c	O
##rea	X
##tine	X
Molecular	O
pathways	O
:	O
inflammation	O
-	X
associated	X
ni	O
##tric	X
-	X
oxide	X
production	O
as	O
a	O
cancer	O
-	X
supporting	X
red	O
##ox	X
mechanism	O
and	O
a	O
potential	O
therapeutic	O
target	O
The	O
role	O
of	O
ni	O
##tric	X
oxide	O
in	O
t	O
##umour	X
progression	O
The	O
receptor	O
RA	O
##GE	X
:	O
br	O
##id	X
##ging	X
inflammation	O
and	O
cancer	O
Gen	O
##ist	X
##ein	X
in	O
##hibit	X
##s	X
advanced	O
g	O
##ly	X
##cation	X
end	O
product	O
formation	O
by	O
trapping	O
met	O
##hyl	X
##gly	X
##ox	X
##al	X
The	O
micro	O
##bio	X
##me	X
and	O
cancer	O
Association	O
between	O
in	O
##tra	X
##ep	X
##ith	X
##eli	X
##al	X
E	B-species
##scher	X
##ichi	X
##a	X
co	I-species
##li	X
and	O
color	B-disease
##ec	X
##tal	X
cancer	I-disease
The	O
role	O
of	O
micro	O
##bio	X
##ta	X
in	O
cancer	O
therapy	O
The	O
pro	O
##gno	X
##stic	X
landscape	O
of	O
genes	O
and	O
in	O
##fi	X
##lt	X
##rating	X
immune	O
cells	O
across	O
human	B-species
cancer	O
##s	X
Me	O
##as	X
##ure	X
##ment	X
of	O
“	O
overlap	X
”	O
in	O
comparative	O
ecological	O
studies	O
The	O
chemistry	O
,	O
physiology	O
and	O
path	O
##ology	X
of	O
pH	O
in	O
cancer	O
Ch	O
##ronic	X
acid	O
##osis	X
in	O
the	O
t	O
##umour	X
micro	O
##en	X
##vir	X
##on	X
##ment	X
select	O
##s	X
for	O
over	O
##ex	X
##press	X
##ion	X
of	O
LA	B-gene
##MP	X
##2	X
in	O
the	O
plasma	O
membrane	O
V	O
##ir	X
##ule	X
##nce	X
genes	O
are	O
a	O
signature	O
of	O
the	O
micro	O
##bio	X
##me	X
in	O
the	O
color	B-disease
##ec	X
##tal	X
tumor	I-disease
micro	O
##en	X
##vir	X
##on	X
##ment	X
Why	O
do	O
cancer	O
##s	X
have	O
high	O
a	O
##ero	X
##bic	X
g	O
##ly	X
##co	X
##lysis	X
?	O

G	O
##ly	X
##co	X
##lysis	X
is	O
the	O
primary	O
bio	O
##ener	X
##get	X
##ic	X
pathway	O
for	O
cell	O
m	O
##ot	X
##ility	X
and	O
c	O
##yt	X
##os	X
##kel	X
##etal	X
re	O
##mo	X
##del	X
##ing	X
in	O
human	B-species
pro	B-disease
##state	X
and	I-disease
breast	I-disease
cancer	I-disease
cells	O
G	O
##ly	X
##co	X
##ly	X
##tic	X
p	O
##hen	X
##otype	X
in	O
breast	B-disease
cancer	I-disease
:	O
activation	O
of	O
A	O
##kt	X
,	O
up	O
-	X
regulation	X
of	O
G	O
##L	X
##UT	X
##1	X
,	O
T	O
##K	X
##TL	X
##1	X
and	O
down	O
-	X
regulation	X
of	O
M	O
##2	X
##P	X
##K	X
Pan	B-disease
##cre	X
##atic	X
cancer	I-disease
metabolism	O
:	O
breaking	O
it	O
down	O
to	O
build	O
it	O
back	O
up	O
Auto	O
##mated	X
on	O
-	X
line	X
non	O
##in	X
##vasive	X
optical	O
glucose	O
monitoring	O
in	O
a	O
cell	O
culture	O
system	O
Sol	O
##ving	X
the	O
puzzle	O
of	O
meta	O
##sta	X
##sis	X
:	O
the	O
evolution	O
of	O
cell	O
migration	O
in	O
neo	B-disease
##p	X
##las	X
##ms	X
Di	O
##sper	X
##sal	X
evolution	O
in	O
neo	B-disease
##p	X
##las	X
##ms	X
:	O
the	O
role	O
of	O
di	O
##s	X
##re	X
##gu	X
##lated	X
metabolism	O
in	O
the	O
evolution	O
of	O
cell	O
m	O
##ot	X
##ility	X
Darwin	O
##ian	X
dynamics	O
of	O
in	O
##tra	X
##tum	X
##oral	X
he	O
##tero	X
##gene	X
##ity	X
:	O
not	O
solely	O
random	O
mutations	O
but	O
also	O
variable	O
environmental	O
selection	O
forces	O
Trade	O
##offs	X
and	O
co	O
##ex	X
##ist	X
##ence	X
in	O
consumer	O
-	X
resource	X
models	O
:	O
it	O
all	O
depends	O
on	O
what	O
and	O
where	O
you	O
eat	O
Re	O
##action	X
-	X
diffusion	X
model	O
for	O
the	O
growth	O
of	O
a	O
##vas	X
##cular	X
tumor	O
Cancer	B-disease
’	O
s	X
fuel	O
choice	O
:	O
new	O
flavor	O
##s	X
for	O
a	O
pick	O
##y	X
eat	O
##er	X
The	O
fi	O
##bro	X
##blast	X
growth	O
factor	O
signaling	O
pathway	O
Access	O
##ories	X
to	O
the	O
crime	O
:	O
functions	O
of	O
cells	O
recruited	O
to	O
the	O
tumor	B-disease
micro	O
##en	X
##vir	X
##on	X
##ment	X
Lac	O
##tate	X
is	O
a	O
media	O
##tor	X
of	O
metabolic	O
cooperation	O
between	O
s	B-disease
##trom	X
##al	X
car	I-disease
##cin	X
##oma	X
associated	O
fi	O
##bro	X
##blast	X
##s	X
and	O
g	O
##ly	X
##co	X
##ly	X
##tic	X
tumor	B-disease
cells	O
in	O
the	O
tumor	B-disease
micro	O
##en	X
##vir	X
##on	X
##ment	X
Cave	O
##olin	X
-	X
1	X
and	O
cancer	O
metabolism	O
in	O
the	O
tumor	B-disease
micro	O
##en	X
##vir	X
##on	X
##ment	X
:	O
markers	O
,	O
models	O
,	O
and	O
mechanisms	O
Power	O
surge	O
:	O
supporting	O
cells	O
“	O
fuel	O
”	O
cancer	B-disease
cell	O
mit	O
##och	X
##ond	X
##ria	X
Ad	O
##ip	X
##ocytes	X
promote	O
o	B-disease
##var	X
##ian	X
cancer	I-disease
meta	O
##sta	X
##sis	X
and	O
provide	O
energy	O
for	O
rapid	O
tumor	O
growth	O
The	O
biology	O
and	O
function	O
of	O
fi	O
##bro	X
##blast	X
##s	X
in	O
cancer	B-disease
Cancer	O
-	X
associated	X
fi	O
##bro	X
##blast	X
##s	X
and	O
tumor	O
growth	O
–	O
by	O
##stand	X
##ers	X
turning	O
into	O
key	O
players	O
In	O
##tra	X
##vi	X
##tal	X
imaging	O
reveals	O
how	O
BR	O
##AF	X
in	O
##hibition	X
generates	O
drug	O
-	X
tolerant	X
micro	O
##en	X
##vir	X
##on	X
##ments	X
with	O
high	O
in	O
##te	X
##g	X
##rin	X
beta	O
##1	X
/	X
FA	X
##K	X
signaling	O
Pro	O
##gno	X
##stic	X
relevance	O
of	O
cancer	O
-	X
associated	X
fi	O
##bro	X
##blast	X
##s	X
in	O
human	B-species
cancer	B-disease
Tu	O
##mor	X
an	O
##gio	X
##genesis	X
:	O
therapeutic	O
implications	O
In	O
##duction	X
of	O
an	O
##gio	X
##genesis	X
during	O
the	O
transition	O
from	O
h	O
##yper	X
##p	X
##lasia	X
to	O
neo	O
##p	X
##lasia	X
The	O
pro	O
##gno	X
##stic	X
value	O
of	O
his	O
##to	X
##logical	X
tumor	B-disease
ne	I-disease
##c	X
##rosis	X
in	O
solid	O
organ	O
ma	O
##li	X
##gnant	X
disease	O
:	O
a	O
systematic	O
review	O
Tu	O
##mor	X
morphology	O
and	O
p	O
##hen	X
##otypic	X
evolution	O
driven	O
by	O
selective	O
pressure	O
from	O
the	O
micro	O
##en	X
##vir	X
##on	X
##ment	X
E	O
##volving	X
di	O
##sper	X
##sal	X
:	O
where	O
to	O
go	O
next	O
?	O

Evolution	O
of	O
di	O
##sper	X
##sal	X
:	O
theoretical	O
models	O
and	O
empirical	O
tests	O
using	O
birds	O
and	O
mammals	O
Cause	O
##s	X
and	O
consequences	O
of	O
animal	O
di	O
##sper	X
##sal	X
strategies	O
:	O
relating	O
individual	O
behaviour	O
to	O
spatial	O
dynamics	O
Tu	O
##mor	X
oxygen	O
##ation	X
predict	O
##s	X
for	O
the	O
likelihood	O
of	O
distant	O
meta	O
##sta	X
##ses	X
in	O
human	B-species
soft	B-disease
tissue	I-disease
sa	I-disease
##rc	X
##oma	X
A	O
##cute	X
h	O
##y	X
##pox	X
##ia	X
enhance	O
##s	X
spontaneous	O
l	O
##ymph	X
node	O
meta	O
##sta	X
##sis	X
in	O
an	O
or	O
##th	X
##oto	X
##pic	X
m	B-species
##uri	X
##ne	X
model	O
of	O
human	B-species
c	B-disease
##er	X
##vic	X
##al	X
car	I-disease
##cin	X
##oma	X
Association	O
between	O
tumor	O
h	O
##y	X
##pox	X
##ia	X
and	O
ma	O
##li	X
##gnant	X
progression	O
in	O
advanced	O
cancer	B-disease
of	I-disease
the	I-disease
u	I-disease
##ter	X
##ine	X
c	I-disease
##er	X
##vi	X
##x	X
Pro	O
##gno	X
##stic	X
value	O
of	O
tumor	O
oxygen	O
##ation	X
in	O
39	O
##7	X
head	B-disease
and	I-disease
neck	I-disease
tumors	I-disease
after	O
primary	O
radiation	O
therapy	O
.	O

